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Chronic pain affects between 20 and 30 percent of the adult population in western countries and 
represents a wide array of specific etiologies (Berge, 2011). Neuropathic pain secondary to 
traumatic nerve injury, chemotherapeutic toxicity, or diseases (e.g., diabetes mellitus) is often 
refractory to conventional analgesics, with patients receiving less than 50% pain relief compared 
to placebo (Finnerup et al. 2010). The endocannabinoid system has shown potential as a 
therapeutic target for neuropathic pain wherein CB1 agonism via administration of exogenous 
agonists or pharmacological blockade of endocannabinoid catabolic enzymes exhibits efficacy in 
reversing allodynia in the chronic constriction injury (CCI) model of neuropathic pain (Rahn & 
Hohmann, 2009). More recently CB1 positive allosteric modulators (PAMs) have shown 
antinociceptive efficacy in CCI with ZCZ011 and its analogs, GAT211 and ABD1236, 
producing dose and time-dependent reversal of allodynia (Ignatowska-Jankowska et al. 2015; 
Slivicki et al. 2018; Tseng et al. 2019). This study reports the activity of the 2-phenyl indole 
class of CB1 PAMs represented by ZCZ011 in behavioral paradigms for overt and subjective 
cannabimimetic side effects, and neuropathic pain. The goal of the study was to examine the 
relationship between the antiallodynic effects, overt and subjective cannabimimetic effects of 
CB1 PAMs. Overt cannabimimetic activity was assessed in the tetrad assay which consists of the 
measures: locomotor activity, catalepsy, antinociception, and hypothermia). Subjective 
cannabimimetic effects were measured in the drug discrimination paradigm. ZCZ011 analogs 
were either tested alone in these assays to screen for agonist activity or in combination with CB1 
orthosteric agonist CP55,940 to screen for PAM effects. ZCZ011 analogs did not exhibit CB1 
agonist activity as measured in the tetrad assay and drug discrimination paradigm when 
administered alone. ZCZ011 was the only PAM to potentiate all three measures of the triad assay 
(catalepsy, antinociception, hypothermia) whereas the remaining analogs potentiated only a 
subset of those effects. ZCZ011, GAT211, LDK1747, and LDK1752 were evaluated in the drug 
discrimination paradigm. Of these compounds only ZCZ011 and LDK1752 had a potentiating 
effect on subjective responding to CP55,940. Lastly ZCZ011 analogs were tested for 
antiallodynic activity in a chronic constriction injury (CCI) model of neuropathic pain. ZCZ011, 
ABD1236, and GAT211 produced full reversal of allodynia in CCI-mice whereas the remaining 
analogs had no effect. Comparing results from this study, ZCZ011 is the only compound which 
exhibits PAM activity in each of the three behavioral paradigms. The remaining analogs show 
disparate effects with respect to overt and/or subjective cannabimimetic effects and antiallodynic 
activity. The results of this study indicate that there is no correlation for CB1 PAM activity 
between the three behavioral paradigms and that it is possible for CB1 PAMs to affect only a 
subset of cannabinoid-related behaviors. 
Chapter 1. General Introduction 
 
Endogenous Cannabinoid System  
 
Endogenous Cannabinoid Receptors  
 Cannabinoid receptors are highly conserved in vertebrates and have also been identified 
in some invertebrate species (Elphick, 2012; McPartland, 2004). Human and rodent CB1 
receptors have a high degree of sequence similarity sharing greater than 90% nucleic acid 
identity and 97% amino acid identity (Abood et al. 1997; Chakrabarti et al. 1995; Ho & Zhao, 
1996). A strong line of evidence for the existence of cannabinoid receptors came from studies 
showing that cannabinoids inhibit adenylyl cyclase activity in neuronal cell models (Howlett & 
Fleming, 1984). The cannabinoid type-1 (CB1) receptor was then identified through radioligand 
binding studies using [3H]-CP55,940 and subsequently cloned from rat and human brain (Devane 
et al. 1988; Gérard et al. 1991; Matsuda et al. 1990). A second subtype, cannabinoid type-2 
(CB2) receptor was identified and cloned using a PCR-based approach in differentiated myeloid 
cell lines (Munro et al. 1993). Both CB1 and CB2 receptors are the primary targets of ∆
9-THC, 
the primary psychoactive constituent of Cannabis sativa (Rinaldi-Carmona et al. 1994). In 
conjunction with receptor binding data, in vivo behavioral measures such as the tetrad assay and 
drug discrimination paradigm have helped confirm that CB1 receptors mediate the effects of 
cannabinoids in the CNS (Compton et al. 1993; Wiley et al. 1995a-c).   
 
Anatomic Distribution of Cannabinoid Receptors  
 The CB1 receptor is the most highly expressed G-protein coupled receptor (GPCR) in the 
CNS, with highest expression in the cerebral cortex, cerebellum, hippocampus, and basal ganglia 
nuclei (Glass et al. 1997; Herkenham et al. 1990; Tsou et al. 1998). The effects of cannabinoids 
on memory and cognition, motor control, and analgesia are correlated with the distribution of 
CB1 receptors in the cerebral cortex and hippocampus, cerebellum, and basal ganglia, 
respectively. CB1 receptors are expressed presynaptically on GABAergic neurons and to a lesser 
extent on glutamatergic neurons where the mediate inhibition of neurotransmitter release 
(Katona et al. 1999; Puighermanal et al. 2009; Straiker & Mackie, 2005). CB1 receptors are also 
expressed in astrocytes where they play a role in modulating synaptic transmission and plasticity 
(Han et al. 2012). In the periphery, CB1 receptors are expressed in circulating immune cells and 
several tissues including adrenal gland, bone marrow, heart, liver, lung, prostate, ovary, testis, 
thymus, tonsil, uterus, and vas deferens (Bouaboula et al. 1999; Galiegue et al. 1995). The CB2 
receptor is mainly expressed in cells associated with immune system function including lung, 
spleen, testis, thymus, tonsil, leukocytes and macrophages (Brown et al. 2002; Galiegue et al. 
1995; Munro et al. 1993). In the CNS, CB2 receptors are primarily expressed in microglia and 
are upregulated during immune responses to stimulate chemotactic responding (Cabral et al. 
2008; Palazuelos et al. 2009). CB2 expression has also been reported in neuronal cells where 
they may modulate dopamine-related behaviors in mice as well as synaptic plasticity in 
hippocampal neurons (Stempel et al. 2016; Zhang et al. 2014; Xi et al. 2011).  
 
Endocannabinoids  
 The discovery of cannabinoid receptors prompted research efforts to identify the putative 
endogenous ligands of CB1 and CB2. The first candidate molecule was N-
arachidonoylethanolamine (anandamide; AEA), isolated from porcine brain, which was shown to 
displace [3H]-U243 from rat membranes and inhibit electrically contractions of isolated mouse 
vas deferens (Devane et al. 1992). The second endocannabinoid identified was 2-arachidonoyl 
glycerol (2-AG). Similar to AEA, 2-AG was found to displace synthetic cannabinoids in 
competitive inhibition experiments and also produced tetrad effects in vivo when administered 
exogenously (Mechoulam et al. 1995; Sugiura et al. 1995). Arachidonic acid and N-
palmitoylethanolamine lack cannabimimetic activity indicating that free arachidonic acid, of 
which AEA and 2-AG are precursors, does not activate cannabinoid receptors and that the 
arachidonic acid moiety is required of N-acylethanolamines and N-acylglycerols for receptor 
activation (Sugiura et al. 1995). Hence, AEA and 2-AG are degraded enzymatically and 
represent the putative endogenous ligands of cannabinoid receptors. Both the synthesis and 
degradation of endocannabinoids are subject to enzymatic regulation. AEA is synthesized by N-
acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) (Cadas et al. 1996; 
Schmid et al. 1983). 2-AG is synthesized by diacylglycerol lipase (DAGL), of which there exists 
two isoforms: DAGLα, expressed in neuronal cells and DAGLß, expressed in microglia and 
macrophages (Bell et al. 1979; Prescott & Majerus 1983; Viader et al. 2016). In neuronal cells, 
the endocannabinoids are synthesized on demand from membrane phospholipids and signal 
retrograde to CB1 receptors on the presynaptic membrane to inhibit neurotransmitter release 
(Bisogno et al. 2003; Katona et al. 2006). AEA and 2-AG are subsequently degraded by fatty 
acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (Gulyas et al. 




Cannabinoid Receptor Structure and Binding Sites   
 The CB1 and CB2 receptors belong to the G-protein coupled receptor (GPCR) family and 
are primarily coupled to Gαi/o heterotrimeric G proteins but also signal through ß-arrestins 
(Howlett et al. 1985; Jin et al. 1999). The crystal structures of CB1 and CB2 have been obtained 
in complex with stabilizing antagonists AM6538 and AM10257, respectively (Hua et al. 2016, 
Li et al. 2019). Characteristic of GPCRs, cannabinoid receptors possess seven transmembrane 
domains connected by three extracellular and intracellular loops each, an extracellular N-
terminal tail, and an intracellular C-terminal tail. Extracellular loop 2 (ECL2) of CB1 is notably 
involved in agonist/inverse agonist binding (Ahn et al. 2009). Docking studies have shown that 
CB1 agonists including AEA, 2-AG, ∆
9-THC, CP55,940, JWH-018, and WIN55,212-2 interact 
mainly with ECL2, the N-terminal loop, and transmembrane helices III, VI, and VII (Hua et al. 
2016). Together these domains make up the orthosteric binding site which recognizes agonist 
and inverse agonist ligands. In addition to the orthosteric binding site, other allosteric binding 
sites have been identified on CB1 receptors (Hurst et al. 2019; Shao et al. 2019). Studies on CB2 
receptors have identified various similarities and differences between CB1 and CB2 receptors 
which help to explain differences in selectivity of cannabinoid receptor agonists and antagonists 
(Li et al. 2019). The CB2 receptor also possesses multiple binding sites as evidenced by reports 
on selective CB2 allosteric modulators (Gado et al. 2019).  
 
Cannabinoid Receptor Signaling Pathways 
 GPCR signaling occurs in three separate spatiotemporal waves (Lohse & Hofmann, 2015; 
Nogueras-Ortiz & Yudowski, 2016). The first wave of CB1 signaling is mediated through Gαi/o 
which leads to decreased cAMP through inhibition of adenylyl cyclase, decreased Ca2+ 
conductance, and increased K+ conductance (Mackie et al. 1995; Twitchell et al. 1997; Guo & 
Ikeda, 2004). The second wave occurs after ligand-induced receptor phosphorylation which leads 
to receptor desensitization and ß-arrestin recruitment. ß-arrestins in this wave of signaling 
function in receptor internalization as well as activation of several downstream effectors (Ahn et 
al. 2013; Breivogel et al. 2008; Delgado-Peraza et al. 2016; Laprairie et al. 2014). The third 
wave of cannabinoid signaling is mediated through CB1 receptors localized to intracellular 
compartments (Brailoiu et al. 2011; Rozenfeld & Devi, 2008). 
 
Allosteric Modulation of Cannabinoid Type I Receptors 
 
Allosteric Modulation and Biased Signaling 
 The operational model of receptor theory (Eq. 1.1) holds that a pharmacological response 
is given by the concentration of agonist, its dissociation constant for the receptor, the maximal 
response, and a tissue-specific component 𝜏 which represents the concentration of agonist bound 
receptor that produces a half-maximal tissue response (Black & Leff, 1983; Kenakin, 2004). The 
operational model allows for comparison of agonist responses between different receptor 
systems. The site to which an agonist binds a receptor to elicit a response is termed the 
orthosteric site. Allosteric modulators bind to topologically distinct or allosteric sites where they 
induce conformational changes that alter receptor activity (Kenakin, 2004). 
 
Response = ([A] x 𝜏 x EMax) / ([A](𝜏+1) + KA Equation 1.1 
 
To understand allosteric modulation of GPCRs one must take into account ligand binding 
at both orthosteric and allosteric sites, receptor activation states, and G protein 
association/activation. Models for the biochemical mechanisms of GPCRs include the extended 
ternary complex (ETC) model and cubic ternary complex (CTC) model (De Lean et al. 1980; 
Weiss et al. 1996). The ETC and CTC models are shown in Figure 1.1. In the ETC model the 
receptor can exist in an active (Ra) or inactive state (Ri). These receptor states may coexist 
according to the allosteric constant L given by L = [Ra] / [Ri]. Constitutive receptor activity is 
given by the concentration of active state RaG species. Allosteric modulators can then, according 
to this model, affect receptor activity through changes in receptor affinity towards orthosteric 
ligands or G proteins; that is allosteric modulators may affect both affinity and efficacy 
(Kenakin, 2013). Not shown in the ETC or CTC model is the association of the receptor with ß-
arrestins which mediate arrest of G protein signaling, receptor internalization, and intracellular 
signaling (Lefkowitz et al. 1998; Lohse et al. 1990; Luttrell et al. 1999). Allosteric modulators 
may impart bias towards either G protein or ß-arrestin signaling in the presence of an orthosteric 
agonist, which even alone may exhibit signaling bias (Kenakin, 2019).  
 




Figure 1.1 Pictorial representations of the extended ternary complex (ETC) model (A) and the 
cubic ternary complex (CTC) model (B). Figures drawn by author using ChemDraw 
Professional 16.0. 1.4 
 
CB1 Negative Allosteric Modulators  
 Org27569, Org27759, and Org29647 were the first CB1 allosteric modulators 
characterized. These compounds were shown to increase the binding of [3H]-CP55,940 but 
caused significant reductions in the EMax values for CP55,940- and AEA-induced [
35S] GTPS 
binding (Baillie et al. 2013; Price et al.2005). Despite enhancement of orthosteric agonist 
binding, the decrease in CB1 signaling functionally classifies these compounds as negative 
allosteric modulators (NAMs) of CB1 receptors. Org27569 reduces inhibition of cAMP 
accumulation for several natural and synthetic CB1 agonists (Khajehali et al. 2015). Org27569 
also reduces CP55,940-induced ß-arrestin recruitment and downstream signaling (Ahn et al. 
2012). In vivo Org27569 decreases feeding behavior in rats and mice, as well as decreases 
CP55,940-induced hypothermia in rats in the triad assay (Gamage et al. 2014; Ding et al. 2014). 
CB1 NAMs have also been studied in the drug discrimination paradigm (see Chapter 2).  
 
CB1 Positive Allosteric Modulators  
 Using in vivo measures such as the tetrad assay and drug discrimination paradigm, CB1 
PAMs have been shown to augment the overt and subjective cannabimimetic effects of 
orthosteric CB1 agonists but lack intrinsic activity in these assays when administered alone 
(Table 1.2).Three classes of CB1 positive allosteric modulators (PAMs) include the tropane 
derivatives (analogs of RTI-371), lipoxin A4, and 2-phenyl indoles (analogs of ZCZ011) 
(Ignatowska-Jankowska et al. 2015; Navarro et al. 2009; Pamplona et al. 2012). In contrast to 
CB1 NAMs, these compounds enhance both the binding and signaling of orthosteric agonists. 
ZCZ011 is fairly well characterized both in vitro and in vivo and several of its analogs have been 
tested in the CCI model of neuropathic pain, tetrad/triad assay, and drug discrimination paradigm 
(Table 1.1. and 1.2). Compounds including ZCZ011, GAT211, and ABD1236 have 
demonstrated antiallodynic effects in models of neuropathic pain (Ignatowska-Jankowska et al. 
2015; Slivicki et al. 2018; Tseng et al. 2019). The LDK series of ZCZ011 analogs lack 
antiallodynic activity but demonstrate some PAM activity with CP55,940 in the triad assay. In 
drug discrimination, only ZCZ011 has been studied where it has been shown to potentiate the 
subjective effects of AEA and CP55,940. The subjective drug effects of the remaining analogs 
have yet to be evaluated. 
 
The Endogenous Cannabinoid System in Acute and Chronic Pain  
 
Ascending and Descending Pain Pathways  
 The spinothalamic and spinoparabrachial tracts are two major ascending pathways in 
mammals, which relay noxious stimulation (Sun et al. 2020; Yam et al. 2018). Nociception is 
relayed through a series of neurons starting with primary sensory afferents which originate in the 
periphery and run through the dorsal root ganglion (DRG) into the dorsal horn of the spinal cord 
where they synapse with second-order neurons. These second-order neurons decussate in the 
spinal cord, ascend the contralateral ventral column then synapse with third-order neurons in the 
thalamus. Finally, the third-order neurons project to the primary somatosensory cortex of the 
postcentral gyrus. The spinoparabrachial tract originates in the spinal cord and relays pain 
information to the parabrachial nuclei of the pons where the synapse with third-order neurons 
which then project to the hypothalamus and amygdala which mediate the emotional response to 
pain. Modulation of pain is mediated by the descending pain pathway, which originates in the 
cortex, hypothalamus, and amygdala and projects down through the brainstem and spinal cord 
via the periaqueductal grey (PAG). The endocannabinoid system is expressed throughout both 
ascending and descending pain pathways and modulates pain through peripheral, spinal, and 
supraspinal mechanisms of action. CB1 receptors are expressed by primary afferent neurons on 
their peripheral endings, central terminals, and in the DRG (Hohmann et al. 1999; Hohmann & 
Herkham 1998, 1999a). In the spinal cord, CB1 receptors are located within the superficial 
laminae of the dorsal horn (Glass et al. 1997; Tsou et al. 1998). In the brain, CB1 receptors are 
found in all brain regions associated with pain processing including the cerebral cortex, 
thalamus, hypothalamus, amygdala, basal ganglia, and PAG (Glass et al. 1997). CB2 receptors 
have also been found in the same brain regions involved in pain as the CB1, although to a lesser 
extent (Brusco et al. 2008; Gong et al. 2006; Onaivi et al. 2006). Lastly, the biosynthetic and 
degradative enzymes of the endocannabinoids are expressed throughout both ascending and 
descending pain pathways in tissues innervated by primary afferents as well as the spinal cord 
and brain (Di Marzo et al. 2000; Egertová et al. 1998; Felder et al. 1996; Stella et al. 1997).  
 Supraspinal mechanisms of action for cannabinoids have been demonstrated by studies 
which show antinociception in rodent models of acute and chronic pain following administration 
of CB1 receptor ligands via intracerebroventricular (i.c.v.) injection, intrathecal (i.t.) injection or 
microinjection into specific brain regions. ∆9-THC and synthetic CB1 receptor agonists 
WIN55,212-2 and CP55,940 (i.c.v.) produce thermal antinociception in the tail-flick test at doses 
that do not significantly alter motor activity, indicating that increased tail-withdrawal latencies 
were not the result of motor impairment (Martin et al. 1993; Raffa et al. 1999). Antinociception 
in the tail-flick test is also produced following microinjection of CB1 agonists into the amygdala, 
thalamus, rostral ventromedial medulla (RVM), and PAG (Lichtman et al. 1996; Martin et al. 
1998, 1999). The CB1 receptor antagonist/inverse agonist rimonabant (i.c.v. or i.p.) blocks the 
antinociceptive effects of ∆9-THC and CP55,940 (i.c.v. or i.t.), thus demonstrating a CB1-
dependent mechanism of action (Welch et al. 1998). Additionally, cannabinoids produce 
antinociception through interactions with the endogenous opioid system (Fang et al. 2012; 
Welch et al.1994, 1995). Alterations in the endocannabinoid system occur in certain brain 
regions following nerve injury in models of neuropathic pain. For example, AEA and 2-AG 
levels are increased following sciatic nerve injury in the chronic constriction injury (CCI) model 
of neuropathic pain in the PAG and RVM (Petrosino et al. 2007). Formalin-evoked pain 
behaviors are depressed in rats after partial sciatic nerve ligation (pSNL) and this effect is 
blocked by administration of rimonabant into the nucleus reticularis gigantocellularis, a region 
involved in descending pain modulation (Monhemius et al. 2001). Lastly, upregulation of 
thalamic CB1 receptor mRNA in pSNL rats suggests that increased CB1 receptor density in 
certain brain regions may serve to increase the analgesic effects of endocannabinoids during 
neuropathic pain states (Siegling et al. 2001).  
 Both in vivo and in vitro measures have been used to demonstrate spinal mechanisms of 
action for the antinociceptive effects of cannabinoids. Levonantradol (i.t.) produces increases in 
response latencies of rats in both hot-plate and tail-flick tests (Yaksh, 1981). ∆9-THC (i.t.) 
produces thermal antinociception in the tail-flick test in mice following spinal cord transection at 
T12, which indicates the antinociceptive effects are not due solely to supraspinal mechanisms 
(Smith et al. 1992). Topical application of WIN55,212-2 to the dorsal aspect of the spinal cord 
reduces heat-evoked activity in isolated neurons of the hind paw of rats (Hohmann et al. 1998). 
CP55,940 (i.t.) attenuates capsaicin-induced sensitization of spinal nociceptive neurons (Johanek 
et al. 2005). In the chronic constriction injury (CCI) model of neuropathic pain, spinal AEA and 
2-AG levels are elevated and Inhibition of FAAH or MAGL has been shown to reduce 
mechanical hypersensitivity (Ignatowska-Jankowska et al. 2015; Kinsey et al. 2009; Petrosino et 
al. 2007; Starowicz et al. 2012).  
 The peripheral antinociceptive effects of cannabinoids involve both CB1- and CB2-
dependent mechanisms. CB1 receptors undergo peripheral axon flow in DRG neurons and are 
expressed on peripheral terminals of nociceptors (Agarwal et al. 2007; Hohmann & Herkenham 
1999b). Direct administration of AEA into the hind paw of rats reduces formalin-evoked 
nociceptive behavior (Calignano et al. 1998). Local administration of WIN55,212-2 into the 
ipsilateral hind paw reduces mechanical hypersensitivity in pSNL rats (Fox et al. 2001). The 
CB2-selective agonist AM1241 (local or i.p.) produces thermal analgesia in rats and this effect is 
blocked by the CB2-selective antagonist AM630 but not AM251, a CB1-selective antagonist 
(Malan et al. 2001). Moreover, AM1241 injected locally to the contralateral hind paw does not 
produce thermal antinociception in the ipsilateral paw and AM630 injected locally to the 
ipsilateral paw blocks the antinociceptive effects of AM1241 administered systemically (i.p.). 
These findings strongly implicate CB2 receptors as the peripheral site of action of cannabinoids.  
 
Chronic Constriction Injury Model of Neuropathic Pain 
 Neuropathic pain can be modeled through spinal nerve ligation (SNL), partial sciatic 
nerve ligation (pSNL), and the chronic constriction injury (CCI) (Bennett & Xie, 1988; Kim & 
Chung, 1992; Seltzer et al. 1990). This thesis employees the CCI model of neuropathic pain, 
which involves the tying of loose ligatures around the sciatic nerve which results in mechanical 
and thermal hypersensitivity in the hind paw either unilaterally or bilaterally, depending on the 
technique (De Vry et al. 2004). This model has been used to study the antinociceptive effects of 
CB1 and CB2 receptor agonists, allosteric modulators, and inhibitors of biosynthetic or catabolic 
enzymes of the endocannabinoids (Donvito et al. 2018). 
 
Investigating the Properties of Cannabinoids in vitro & in vivo  
 
Binding and Functional Assays In Vitro  
 The binding properties of novel cannabinoid receptor ligands are determined through 
binding assays measuring the displacement of a tritium labeled CB1/CB1 agonist such as [
3H]-
CP55,940 (Howlett et al. 2002). The [35S] GTPγS binding assay can be used to measure agonist-
stimulated G protein activation as well as visualize receptor binding in autoradiography 
experiments (Howlett et al. 2002; Sim et al. 1995). Inhibition of adenylyl cyclase activity can be 
measured through changes in cAMP concentration inside model cells transfected with CB1 or 
CB2 receptors (Howlett et al. 1985; Pertwee, 1997). There also exist other functional assays to 
measure ß-arrestin recruitment and ERK phosphorylation (Osmond et al. 2005; Zhao et al. 
2008).  
 
Behavioral Paradigms for Cannabimimetic Activity   
 Early studies on cannabinoids involved measuring overt behaviors such as static ataxia in 
dogs or ptosis and sedation in monkeys (Walton et al 1937; Edery et al. 1971). More commonly 
used models at present include the tetrad assay and drug discrimination paradigm. The tetrad 
assay is a measure of cannabimimetic activity wherein direct CB1 agonists produce a full subset 
of effects including hypomotility, catalepsy, thermal antinociception, and hypothermia which 
strongly correlates with psychoactivity in humans (Martin et al. 1991). The drug discrimination 
paradigm is used to measure the subjective effects of CB1 receptor agonists and has been used 
extensively to characterize cannabinoid receptor ligands in rodents and non-human primates 
(reviewed in Chapter 2). Both the tetrad assay and drug discrimination paradigm have been 
useful in drawing structure-activity relationships between cannabinoid receptor ligands and 
assessing abuse liability.  
 
Overview of 2-phenyl indoles Represented by ZCZ011 
The class of CB1 PAMs represented by ZCZ011 are all characterized by their 2-phenyl 
indole backbone (Fig. 1.2). ZCZ011 represents a racemic mixture of its (R)-isomer (ZCZ011A) 
and (S)-isomer (ZCZ011B). Other racemates include GAT211, ABD1236 and ABD1236. 
Compounds such as LDK1747 and LDK1752 possess a trisubstituted amine which by inversion 
renders them achiral. Additions or substitutions at the chiral center or on the indole ring 
distinguish each analog and produce varying degrees of change in their activity in vitro or in vivo 














Figure 1.2 Structures of ZCZ011, its structural isomers and analogs. 
 
Pharmacological Effects In Vitro   
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32 94 777 55 Ignatowska-
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2015; Dai Lu 
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129.54 Laprairie et al. 
2017; Data 
courtesy of Dai 
Lu, PhD. 
LDK1729 - - 55 74 >3000 2.1 Data courtesy of 
Dai Lu, PhD1. 
LDK1730 - - 47.2 101.5 >10000 12.5 
LDK1747 - - 114.6 92.6 1146 31.1 
LDK1752 - - 20 105 226 57.8 
CP55,940 
  
0.14 98.9 1.7 99.7 
 
(-) indicates not reported  
(1) personal communication 
 
 
Pharmacological Effects In Vivo 
 
Table 1.2 Summary of in vivo activity for ZCZ011 


















A more detailed account on the origins of drug discrimination has been written by Donald 
Overton; this section provides a briefer summary of his work (Overton, 1991). Drug 
discrimination developed from studies on state dependent memory, or state dependent learning 
(SDL). SDL is the phenomenon where memory recall performance is dependent on the state of 
consciousness or overall physiological state at the time of acquisition and time of recall. When a 
behavioral response in an animal is learned under either condition of drug (D) or no drug (N), the 
animal performs the behavior most efficiently when the drug condition at the time of training is 
reestablished (Overton, 1984). SDL is related to context dependent learning although the key 
difference is that context in SDL is the cognitive state of the individual in terms of organic mood 
states or synthetic mood states as induced by drugs (Bower, 1981; Grant et al., 1998; Overton 
1964). Whereas context dependent learning involves exteroceptive cues (i.e., the environment), 
SDL involves interoceptive cues (i.e., cognitive state of the organism). The first case report of 
the effects of drugs on memory retrieval came from George Combe who remarked on a story of a 
man who when sober could not recall where he had placed a package but upon becoming 
intoxicated again was able to relocate the lost item. “The only conclusion which seems to arise 
… is that before memory can exist, the organs [have] to be affected in the same manner, or to be 
in a state analogous to that in which they were, when the impression was first received” (Combe, 
1835). Combe’s report appeared throughout medical literature in the decades following and the 
idea that a drug state (e.g., alcohol intoxication) could produce SDL was generally accepted 
(Elliotson, 1840; Macnish 1834, 1835; Overton, 1991; Winslow, 1860). In the later part of the 
century French physiologist Théodule-Armand Ribot refined this idea by proposing that bodily 
“organic sensations”, or interoceptive stimuli, play an important role in memory retrieval (Ribot, 
1882, 1891). Investigations involving SDL in the 19th and early 20th centuries helped lay the 
conceptual groundwork for the study of drug discrimination. After 1950, advances in the field 
and procedural changes marked a transition to the use of what are now considered modern drug 
discrimination procedures (Overton 1971, 1982, 1991; Schuster and Balster 1977).  
One of the earliest drug discrimination studies involved an approach/avoidance task in 
which rats learned to approach an object while intoxicated or avoid while sober, and vice versa 
(Conger, 1951). Conger noted that the change in avoidance behavior may have been due solely 
to the change in the animals’ internal state (intoxicated vs. sober) rather than to any intrinsic 
effects of alcohol intoxication. To demonstrate that drugs can serve as discriminative stimuli, 
subsequent studies employed a 2X2 experimental design in which subjects are trained and tested 
for recall in groups representing all possible transitions: D (drug) →D, D→N (no drug), N→N, 
and N→D (Auld, 1951; Grossman and Miller, 1961; Miller, 1957; Miller and Barry, 1960; 
Murphy and Miller, 1955). The 2X2 experimental design proved useful for detecting drug 
stimulus effects as it takes into account each possible change of state of the subject though it was 
not without limitations. The 2X2 design assumes that SDL is symmetrical in that D→N and 
N→D state changes should produce equally large deficits and it cannot distinguish memory 
impairment from depressant effects of a drug on performance. An improvement to drug 
discrimination methodology came with the incorporation of symmetrical tasks such as the two-
choice T-maze. In using a symmetrical drug discrimination task, drug stimulus properties are 
measured according to response selection rather than response occurrence (Overton 1961, 1964). 
In 1968, Harris and Balster applied operant conditioning to the drug discrimination 
paradigm whereby they trained rats to discriminate DL-amphetamine from saline on two-lever 
(TL) multiple fixed ratio 50/differential-reinforcement-of-low-rate 20s (MULT FR50, DRL 20s). 
They showed that the rats acquired the amphetamine discriminative cue and demonstrated 
condition-appropriate responding under extinction conditions (Harris & Balster, 1968). Studies 
employing the operant drug discrimination paradigm generated ED50 values for dose-response 
curves much lower than reported in T-maze paradigms (Kubena & Barry, 1969a, b; Morrison & 
Stephenson 1969). A major step that helped standardize the two-lever drug discrimination 
procedure was the introduction of fixed ratio (FR) schedules of reinforcement where a pellet 
reward is given, for example, every tenth condition-appropriate response (FR10). A study in 
1975, in which rats trained to discriminate fentanyl using a TL FR10 schedule of reinforcement, 
showed that the discriminative stimulus effects of fentanyl were dose-dependent and 
pharmacologically specific (i.e., generalized only to drugs of the same class) and measurement of 
response rates could detect inhibitory or stimulatory effects of a drug (Colpaert & Niemegeers, 
1975).  
 The standard approaches and utility of two-lever operant drug discrimination procedures 
were apparent by the mid-1970s. In 1976, Shannon and Holtzman trained rats to discriminate 
morphine (3.0 mg/kg) from saline in a shock avoidance procedure. They demonstrated that the 
discriminative stimulus effects of morphine were time and dose-dependent, pharmacologically 
specific, stereoselective, and cross-tolerant with the discriminative cue of methadone (Shannon 
& Holtzman, 1976). These characteristic features of receptor-mediated pharmacology have also 
been demonstrated with other classes of drugs aside from opioids, highlighting the utility of 
discrimination paradigms for the classification of drugs according to their discriminative 
stimulus effects. Major drug classes which produce a discriminative stimulus include stimulants, 
depressants, opioids, hallucinogens, dissociative anesthetics, and cannabinoids. Drug 
discrimination became increasingly popular among behavioral pharmacologists as a tool to 
investigate drugs of abuse. Table 1 gives a partial list of drugs that have been used as a 
discriminative stimulus in drug discrimination paradigms. From the body of literature on drug 
discrimination arise a few core principles. The first is that the discriminative stimulus properties 
of a drug are generally considered to be reflective of its subjective effects. For example, a drug 
that substitutes for the discriminative stimulus of ∆9-THC in rodents is likely to produce the 
same subjective ‘high’ feeling in humans as ∆9-THC. Sensitivity to discriminative stimuli may 
also vary between individuals in human and nonhuman subjects. Second, that drugs may be 
classified according to their discriminative stimulus properties and this feature may be used to 
study tolerance and cross-tolerance among drugs of the same class. Lastly, that the 
discriminative stimulus properties of a drug are stereospecific, and their action reflects CNS 
activity at specific neurotransmitter receptors. 
 
Table 2.1  Partial list of drugs exhibiting discriminative stimulus properties†  
Drug  Class or Receptor Mechanism  Reference 
amphetamine  stimulant  Schechter and Rosecrans, 
1973  
apomorphine  dopamine receptor agonist  Colpaert et al., 1975  
atropine  antimuscarinic  Barry and Kubena, 1972  
buprenorphine  opioid analgesic, MOR partial 
agonist  
Holtzman, 1997 
buspirone  anxiolytic  Hendry et al., 1983  
caffeine  stimulant  Carney and Christensen, 
1980  
cholecystokinin  neuropeptide hormone De Witte et al., 1985  
chlorpromazine  antipsychotic Goas and Boston, 1978  
clozapine  antipsychotic  Browne and Koe, 1982  
cocaine  stimulant  Järbe, 1978  
desipramine  antidepressant  Shearman et al., 1978  
dextromethorphan  antitussive Holtzman, 1994  
diazepam anxiolytic  Young et al., 1986  
diphenhydramine  antihistamine  Winter, 1985  
DOM hallucinogen  Young et al., 1980  
ephedrine  sympathomimetic  Young and Glennon, 1998  
ethanol  sedative  Schechter, 1974  
fenfluramine  anorectic Goudie, 1977  
fentanyl  opioid analgesic, MOR partial 
agonist  
Colpaert et al., 1975  
imipramine  tricyclic antidepressant  Zhang and Barret, 1991 
LSD-25 hallucinogen  Hirschhorn and Winter, 1971 
MDA empathogen-entactogen Glennon and Young, 1984  
MDMA empathogen-entactogen Glennon and Misenheimer, 
1989  
morphine  opioid analgesic, MOR agonist  Hirschhorn and Rosecrans, 
1974   
naloxone  MOR antagonist  Carter and Leander,1982  
nicotine  nAChR agonist Schechter and Rosecrans, 
1972  
NMDA NMDAR agonist  Willetts and Balster, 1989  
pentazocine  opioid analgesic, MOR agonist  Kuhn et al., 1976  
pentobarbital sedative  Herling et al., 1980  
phencyclidine dissociative anesthetic  Brady and Balster, 1981  
pregnenolone  neurosteroid hormone  Vanover, 1997  
∆9-THC CB1 receptor agonist  Järbe et al., 1977  
Toluene  abused inhalant  Rees et al., 1987  
MOR µ-opioid receptor, LSD lysergic acid diethylamide, MDA 3, 4-
methylenedioxyamphetamine, MDMA 3, 4-methylenedioxymethamphetamine, nAChR nicotinic 
acetylcholine receptor, CB1 cannabinoid receptor subtype-1, ∆
9-THC delta-9-
tetrahydrocannabinol   
† Source: Richard Young in chapter 3 of Methods of Behavior Analysis in Neuroscience, 2nd 
edition 
 
 The first behavioral pharmacologists investigating in vivo effects of cannabinoids 
employed drug discrimination procedures developed in the 1960s and 1970s. Cannabinol (CBN) 
was the first structurally confirmed phytocannabinoid isolated from cannabis. Early 
pharmacological studies showed that tetrahydrocannabinols, compared to other compounds such 
as cannabidiol (CBD) are the primary psychoactive constituents of cannabis (Cahn, 1933; Loewe 
1946).  It was not until the 1960s however that advances in separation techniques and structural 
determination led to the isolated structures of ∆9-THC and CBD (Gaoni & Mechoulam, 1964; 
Mechoulam & Shvo, 1963). By the 1970s the techniques for isolation, structural confirmation, 
and synthesis of major and other phytocannabinoids were well established (Mechoulam & 
Gaoni, 1965, 1967, 1971). Research around the time focused primarily on developing bioassays 
to quantify the behavioral effects of cannabis and its individual cannabinoid constituents, 
establishing pharmacokinetic pathways for those compounds, and constructing structure-activity 
relationships (Agurell, 1986; Edery et al., 1971; Pertwee, 1972). The first animal model used to 
study the effects of cannabinoids was measuring static ataxia in dogs which consists of sedation, 
catalepsy, motor impairment, and hyperexcitability (Walton, 1937). Another useful model was 
studying overt behaviors in monkeys (e.g., sedation, ptosis, slouched posture, hyperexcitability). 
Static ataxia and overt behavior models were reliable for assessing structure activity relationships 
for cannabinoids and novel structural analogs, demonstrating both stereospecificity, shifts in 
potency, and high correlation with psychoactivity (Edery et al., 1971; Martin et al., 1975). 
Concurrent with the advances in cannabinoid pharmacology following the discoveries of 
Mechoulam, was the development of drug discrimination procedures. By the time ∆9-THC had 
been isolated and synthesized, operant drug discrimination tasks had already proven useful for 
characterizing the discriminative stimulus effects of drugs of abuse such as amphetamine or 
alcohol (Harris & Balster, 1968; Kubena & Barry, 1969a, b; Morrison & Stephenson, 1969). 
Cannabinoid researchers now had a reliable tool for measuring the subjective effects of 
cannabinoids in addition to predicting psychoactivity whereas previous behavioral measures 
were strictly models of intoxication.  
In 1971, ∆9-THC was shown to produce SDL in rats under a conditioned avoidance 
paradigm, suggesting that it might also serve as a discriminative stimulus as had been 
demonstrated with other drugs known to produce SDL (Henriksson & Järbe, 1971). ∆9-THC was 
used as a discriminative stimulus the following year in a study, which trained male Wistar rats in 
an operant-lever shock avoidance procedure to discriminate the effects of ∆9-THC from vehicle 
and a variety of other pharmacological agents (Kubena & Barry, 1972). It was successfully 
demonstrated that ∆9-THC produces a discriminative cue that does not generalize to drugs of 
other classes or to non-psychoactive cannabinoids such as CBD. That same year Henriksson & 
Järbe successfully trained Sprague-Dawley rats to use ∆9-THC as a discriminative stimulus in a 
water T-maze position learning task (Henriksson & Järbe, 1972). Järbe and collaborators 
published much of the early literature on cannabinoid drug discrimination in the following years 
(Järbe & Henriksson, 1974; Järbe et al. 1975, 1977; Järbe & McMillan 1979, 1980). These 
studies corroborated evidence from other behavioral models showing ∆9-THC is the primary 
psychoactive component of cannabis in addition to novel generalization tests. Important structure 
activity relationships were also demonstrated, with analogs of ∆9-THC (e.g., ∆8-THC) or its 11-
hydroxy metabolites generalizing to the discriminative cue of ∆9-THC. Lastly, these studies 
showed that other species including gerbils and pigeons learn to discriminate ∆9-THC from 
vehicle and other compounds (Table 2.2). The work on cannabinoid drug discrimination strongly 
suggested a common mechanism of action for these drugs. However, the mechanism of action 
mediating the pharmacological effects of cannabinoids remained under debate until the 
development of a cannabinoid receptor radioligand binding assay and the cloning of cannabinoid 
receptors from rat brain and later from human brain (Devane et al. 1998; Matsuda et al. 1990; 
Munro et al. 1993).  
Drug discrimination remained a useful and reliable tool in the cannabinoid field 
following the discovery of cannabinoid receptors. The model was extended to Rhesus monkeys 
which was used to characterize novel cannabinoids such as CP55,940 and WIN55,212-2 with the 
intention of providing a more accurate correlate of psychoactivity in humans than the rodent and 
avian drug discrimination studies (Gold et al. 1992; Compton et al. 1992). The discriminative 
stimulus effects of the endogenous cannabinoid AEA and/or its metabolically stable analogs 
were characterized following their discovery, effectively showing that CB1 receptors mediate 
their discriminative stimulus effects (Wiley et al. 1995a; Burkey and Nation, 1997). The 
discriminative stimulus effects of the other endocannabinoid 2-AG were characterized indirectly 
by using inhibitors of its degradative enzyme, MAGL (Wiley et al. 1995b, c; Solinas et al. 2007; 
Walentiny et al. 2011). Hence the role of the endocannabinoid system in cannabinoid drug 
discrimination can be studied through administration of CB1 receptor agonists or indirectly by 
pharmacological blockade of endocannabinoid degradation. Whether by administration of 
exogenous agonist or pharmacologic blockade of MAGL and/or FAAH, the common feature 
among all previously mentioned studies is that they quantify discriminative stimulus effects in 
terms of CB1 agonism and antagonism, through generalization and antagonism tests. More 
recently however, CB1 receptor allosteric modulators have been investigated in the drug 
discrimination paradigm, CB1 receptor allosteric modulators which do not substitute for CB1 
receptor orthosteric agonist training drugs but can produce shifts in the dose-response curves of 
the generalization curves of the training drugs (Gamage et al. 2014; Ignatowska-Jankowska et al. 
2015).  Published reports investigating CB1 receptor allosteric modulators suggest potential 
therapeutic applications and advantages over direct agonism or antagonism making CB1 receptor 
allosteric modulation an exciting area for drug development to which the drug discrimination 
paradigm lends itself well. ZCZ011 for example is a CB1 positive allosteric modulator (PAM), 
which reverses allodynia in a mouse chronic constriction injury (CCI) model of neuropathic pain 
but lacks intrinsic cannabimimetic activity similar to ∆9-THC (Ignatowska-Jankwoska et al. 
2015). Moving forward, cannabinoid drug discrimination offers a reliable in vivo model to screen 
novel CB1 receptor allosteric modulators and their structural analogs. The remainder of this 
review will cover important concepts in drug discrimination, both theoretical and methodological 
as well as discuss separately the discriminative stimulus effects of phytocannabinoids, 
endogenous cannabinoids, cannabinoid antagonists, and cannabinoid allosteric modulators. Table 
2 provides a summary of substitution profiles for cannabinoid and non-cannabinoid drugs 
discussed in this review.  
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Wiley et al. 
(2011) 
F.S. full substitution, P.S. partial substitution, N.S. no substitution, IM intramuscular route of 
administration, s.c. subcutaneous route of administration, DLR drug lever or drug-like 
responding, TL two-lever choice, TH two-hole choice nose-poke, TK two-key choice, SD 
Sprague-Dawley rats, FR fixed ratio, CM 1:1 condensed milk and water, CS 1:1 carnation 
slender and water, SW dilute (0.4%) saccharin solution, SM sweetened milk 
(a) Intraperitoneal route of administration unless otherwise stated  
(b) Food-pellet reinforced unless otherwise stated 
(c) Full substitution defined as ≥80% DLR; No substitution defined as 20% DLR 
(d) Effect on rate of responding with respect to the highest dose tested 
 
 
Core Concepts and Principles of Drug Discrimination  
 The studies listed in Table 2 demonstrate important concepts that make drug 
discrimination a reliable preclinical tool for studying cannabinoids in vivo. It is evident that drug 
discrimination can be used to classify drugs according to their discriminative stimulus properties 
and that these effects are mediated through receptor specific neural mechanisms. Morphine for 
example which acts via µ-opioid receptors does not substitute for the discriminative stimulus of 
∆9-THC in rats or monkeys trained to discriminate ∆9-THC from vehicle (Järbe & Henriksson, 
1974; Browne & Weissman, 1981; Wiley et al. 1995d). Overall, drug discrimination is useful for 
investigating novel compounds of structurally similar and dissimilar cannabinoids including CB1 
receptor agonists, inverse agonists, and allosteric modulators. Drug discrimination also clearly 
demonstrates aspects of receptor mediated pharmacology in that the discriminative stimulus 
effects of cannabinoids are dose-dependent, stereospecific, antagonizable, and subject to 
tolerance with cross-tolerance seen between cannabinoids with similar activity (i.e. CB1 receptor 
agonists are cross tolerant with one another). Although these features can be demonstrated with 
other bioassays, various aspects of drug discrimination make it an excellent model for drug 
development in the cannabinoid field.  
 
Subjective Effects of Drugs  
 There is a general consensus in the field of drug discrimination that the model provides a 
means by which the subjective effects of drugs can be quantified (Colpaert et al. 1976; 
Hirschhorn & Rosecrans, 1976; Shannon & Holtzman, 1976). Subjective effects of drugs refer to 
the effects which are mediated through a drug’s action on the CNS rather than any peripheral 
effects. The subjective effects of morphine for example can be attributed to its agonist action at 
µ-opioid receptors in the CNS rather versus peripheral analgesic mechanisms in dorsal root 
ganglia (DRG) (Colpaert & Niemegeers, 1975; Colpaert et al. 1975). One should use caution 
when interpreting subjective drug effects between animal and human models of drug 
discrimination. For humans, oral reports can provide a detailed description of how a drug makes 
them feel and how its subjective effects correlate with its discriminative stimulus properties 
(Chait et al. 1984, 1985, 1986a, 1986b, 1988). Discrimination studies in humans have also 
revealed sex differences in the subjective effects of ∆9-THC in cannabis users (Fogel et al. 
2017). The same degree of qualitative information on the subjective effects of drugs cannot be 
ascertained from animals; however, the key point is that drug discrimination tasks do not ask the 
subjects how they feel but rather quantitatively ascertains the interoceptive effects of a drug.   
As a reliable model for measuring subjective drug effects, drug discrimination is also 
used as preclinical model for assessing abuse liability of novel cannabinoids. Should a compound 
substitute for the discriminative stimulus of a known drug of abuse, that compound is inferred to 
have potential liability. Drug self-administration has largely overtaken drug discrimination as a 
model for drug abuse in the last twenty years as the neural circuitry involved in drug-reinforced 
behavior is more well defined than the mechanisms responsible for discriminative stimulus 
effects and that it has high face-validity for drug abuse in humans (reviewed in McMahon, 
2015). However, few studies have demonstrated cannabinoid self-administration in nonhuman 
animals (Carney et al., 1977; Young et al., 1981; Tanda et al., 2000). Additionally, drug 
discrimination compared to other behavioral paradigms is highly sensitive to cannabinoids. ∆9-
THC is more potent in regard to its subjective effects as measured by drug discrimination than it 
is in producing the full tetrad set of cannabimimetic effects consisting of hypomotility, catalepsy, 
antinociception, and hypothermia (Long et al. 2009; Marshell et al. 2014). CB1 receptor agonists 
may also produce full substitution at doses that do not negatively affect response rates (Vann et 
al., 2009) whereby the subjective effects of cannabinoids therefore are detected prior to 
alteration of overt behaviors such as locomotion. The subjective effects of drugs (contrary to 
their namesake) are an objectively useful quality which investigators analogously quantify as a 
discriminative stimulus.   
 
Receptor Mechanisms of Discriminative Stimulus Effects   
 The CB1 receptor is the most abundant GPCRs in the CNS and is highly expressed 
throughout the neocortex, basal ganglia, hippocampus, cerebellum, and brainstem (Herkenham et 
al. 1990, 1991; Glass et al. 1997; Tsou et al. 1998). The neuroanatomic distribution of CB1 
receptors correlates with its role in the endocannabinoid system and is responsible for mediating 
the effects of exogenous agonists such as ∆9-THC or synthetic cannabinoids. Pharmacological 
and genetic techniques have been used in conjunction with various behavioral paradigms to parse 
out the role of CB1 receptors in different brain regions (Zimmer et al. 1999; Wilson-Poe et al. 
2012). CB1 receptors are primarily coupled to pertussis toxin (PTX)-sensitive Gαi/o proteins and 
activation by agonists leads to inhibition of adenylyl cyclase as well as modulation of voltage-
gated calcium channels and potassium channels (Mackie et al. 1995; Twitchell et al. 1997; Guo 
& Ikeda, 2004). The net cellular effect of CB1 receptor activation is dependent on the cell-type 
on which they are expressed and the cell's dominant neurotransmitter product.  
CB1 receptors are primarily localized to presynaptic axon terminals of GABAergic and 
glutamatergic neurons where they mediate inhibition of neurotransmitter release (Straiker & 
Mackie, 2005). Astrocytes express CB1 receptors to a lesser extent, though understanding how 
they play an important role in modulating synaptic transmission and plasticity is increasing (Han 
et al. 2012). The endocannabinoids 2-AG and AEA are synthesized on demand from membrane 
phospholipids in the postsynaptic membrane and signal in a retrograde fashion (Bisogno et al. 
2003; Katona et al. 2006). The discriminative stimulus effects of cannabinoids are produced as a 
result of their neuromodulatory capacity. Other sedative drugs which modulate GABAergic 
neurotransmission including barbiturates and benzodiazepines may partially substitute for ∆9-
THC in drug discrimination paradigms but full substitution is only achieved from CB1 receptor 
activation (see Table 2).  
 CB1 receptor agonists both endogenous and synthetic produce a discriminative stimulus 
in a dose dependent manner that can be generalized. Differences in structure may impart 
differences in potency. 11-OH-∆9-THC and 11-OH-∆8-THC (∆9-THC metabolites) both 
generalize to ∆9-THC with the ∆9 isomer being more potent, thereby demonstrating 
stereoselectivity (Järbe & McMillan, 1979). Discriminative stimulus effects of cannabinoids are 
also stereospecific. The (+) configuration of WIN55,212-2 produces a discriminative stimulus 
similar to ∆9-THC whereas (-)-WIN55,212-2 has no effect (Compton et al. 1992). The CB1 
receptor inverse agonist rimonabant (SR141617A) dose-dependently antagonizes the 
discriminative stimulus effects of CB1 receptor agonists (Wiley et al. 1995c; Pério et al. 1996; 
Järbe et al. 2001; Walentiny et al. 2015). Finally, CB1 receptor allosteric modulators may 
enhance or diminish the potency of the discriminative stimulus of CB1 receptor agonists. The 
positive allosteric modulator (PAM) ZCZ011 for example does not elicit a discriminative 
stimulus alone but produces a leftward shift in the dose-response curves of CP55,940 and AEA 
(Ignatowska-Jankowska et al. 2015).  
 
Tolerance and Cross-Tolerance  
The subjective effects of ∆9-THC and other CB1 receptor agonists are only modestly 
affected by tolerance in that full substitution can be seen at doses that do not impair response 
rates (Hruba et al. 2012; Vann et al. 2009). This was demonstrated almost 40 years ago in a 
study that used trained rats to discriminate ∆9-THC from vehicle and used rope-climbing 
performance as a measure of tolerance (Bueno et al. 1972). They found that after daily training 
sessions with ∆9-THC, the rats became tolerant to the drugs impairing effects on rope-climbing 
but still discriminated ∆9-THC from vehicle, suggesting that its discriminative stimulus 
properties were not subject to tolerance. Furthermore, lever response rates remain stable 
throughout chronic administration and it has been shown that chronic administration of ∆9-THC 
at higher doses than the training dose produces only minor decreases in the degree of differential 
responding (Hirschhorn & Rosecrans, 1974). Under standard drug discrimination acquisition 
training, subjects do not develop appreciable tolerance to the discriminative stimulus of the 
training drug apart from under certain modifications. For example, rats trained to discriminate 
3.0 mg/kg ∆9-THC were then administered either vehicle or a high dose of ∆9-THC during a 
period of suspended training (Wiley et al. 1993).  Rats subjected to the high dose treatment of 
∆9-THC showed a 40-fold rightward shift in their dose-response compared to the dose-response 
curve generated under the prior training dose regimen. This shift in the potency suggested the 
rats developed tolerance to the discriminative stimulus effects of ∆9-THC. This result is 
consistent with the effect that higher training dose produces higher ED50 values (Schechter, 
1983; Solinas et al. 2006). As such, the discriminative stimulus effects of CB1 receptor agonists 
can undergo tolerance but solely through repeated administration of high doses, atypical for drug 
discrimination training or testing. The lack of cannabinoid compound tolerance under standard 
training doses makes drug discrimination a very reliable model for studying CB1 receptor 
pharmacology in vivo.   
 
Drug Discrimination in Drug Development   
 Drug discrimination has demonstrated pharmacological specificity for a variety of drug 
classes including cannabinoids and has been employed by pharmaceutical companies, 
government agencies, and academic institutions for the classification of novel compounds. 
Olanzapine, an atypical antipsychotic was approved by the FDA four years following a study, 
which demonstrated that it fully substituted for the cue in animals trained to discriminate the 
atypical antipsychotic clozapine (Moore et al. 1992). The DEA has made use of drug 
discrimination for scheduling purposes in assessing abuse liability of illicit drugs such as 
substituted cathinones. Drug discrimination studies have also provided the DEA with evidence 
for the scheduling of synthetic cannabinoids commonly found on the gray market (Gatch & 
Forster 2014, 2015). With respect to cannabinoids, drug discrimination has proven useful in 
establishing structure activity relationships of novel cannabinoids both structurally similar and 
dissimilar to ∆9-THC such as CP47,497 and those frequently used in research, CP55,940 and 
WIN55,212-2 (Grim et al. 2016; Wiley et al. 1995c; Compton et al. 1992). In addition to 
exogenous cannabinoid agonists, drug discrimination has also been used in the development of 
metabolically stable analogs of the endocannabinoids 2-AG and AEA as well as inhibitors of 
their respective catabolic enzymes, MAGL and FAAH (Wiley et al. 1997; Solinas et al. 2007; 
Long et al. 2009; Hruba et al. 2015; Walentiny et al. 2015). Most recently drug discrimination 
has been used to assess the activity of CB1 receptor allosteric modulators such as ZCZ011, 
Org27569, and novel analogs of those compounds (Gamage et al. 2014; Ignatowska-Jankowska 
et al. 2015). 
 
Discriminative Stimulus Properties Cannabinoid Agonists  
Cannabinoids are derived from three primary sources: species of the genus Cannabis 
(phytocannabinoids), organic synthesis in laboratories (synthetic cannabinoids), and endogenous 
biosynthesis (endocannabinoids). Cannabinoids within either category exhibit some structural 
similarity though comparison between categories shows marked differences in structure. The 
common factor among these cannabinoids is that they are agonists at CB1 receptors and that is 
















Figure 2.1 Chemical structures of major cannabinoids found in Cannabis sativa and related 
compounds (all structures drawn by author using ChemDraw Professional 16.0. 1.4) 
 In addition to ∆9-THC, Cannabis sativa contains myriad cannabinoid compounds 
including CBD, CBN, ∆8-THC as well as non-cannabinoid constituents such as terpenoids 
(Mechoulam et al. 1972; Fischedick et al. 2010; Radwan et al. 2015). The interactions of these 
compounds, psychoactive and non-psychoactive at the receptor and behavioral levels has not 
been fully determined and represents a burgeoning area of research (reviewed in Russo, 2011). 
∆9-THC being the primary psychoactive component of Cannabis sativa, is the most well 
characterized phytocannabinoid, and was almost the exclusive focus of cannabinoid drug 
discrimination research until the development of synthetic CB1 receptor agonists. Early 
discrimination studies demonstrated specificity of the ∆9-THC cue in that pharmacologically 
distinct compounds failed to either substitute for, or antagonize the discriminative stimulus 
produced by ∆9-THC (Järbe & Henriksson, 1974; Järbe et al. 1976; Browne & Weissman, 1981). 
Phytocannabinoids have been shown to display both stereoselectivity and stereospecificity in 
their ability to serve as discriminative stimuli. The (+)-∆9-THC isomer does not substitute for the 
(-)-isomer (i.e., stereoselectivity) whereas (-)-∆8-THC, (-)-∆9,11-THC, CBN, and ∆9-THC’s 11-
hydroxy metabolites all substitute in animals trained to discriminate ∆9-THC, albeit with varying 
potencies (i.e., stereospecificity) (Järbe et al. 1981, 1987; Järbe & McMillan, 1980; Semjonow & 
Binder, 1985). CBD, the major non-psychoactive phytocannabinoid does not substitute for ∆9-
THC nor does it alter ∆9-THC’s substitution patterns or rate of responding (Hiltunen & Järbe, 
1986; Järbe et al. 1977, 1986; Vann et al. 2008). Much of the early literature on cannabinoid 
drug discrimination was published before the existence of endogenous cannabinoid receptors 
was definitively proven but the findings were consistent with a specific receptor mediated 
mechanism. And indeed, it was later shown that in vivo potencies of phytocannabinoids 
correlated with their binding affinities for CB1 receptors (Compton et al. 1993). In lieu of 
synthetic CB1 receptor agonists, ∆
9-THC discrimination has been a reliable animal model of 
cannabis intoxication and the standard for studying the receptor mechanisms of cannabinoids and 
predicting cannabis-like abuse potential of novel compounds.  
 















Fig. 2.2 Chemical structures of synthetic cannabinoid CB1 receptor agonists (all structures 
drawn by author using ChemDraw Professional 16.0. 1.4) 
 Five major categories of synthetic cannabinoids that are classified according to their 
structure include: classical, non-classical, hybrids, aminoalkylindoles, and eicosanoids (Howlett 
et al. 2002; Thakur et al. 2005). Within each category, there are also multiple families of 
synthetic cannabinoids (e.g., HU-#, CP-#, AM-#, WIN-#, JWH-#). Efforts to synthesize novel 
cannabinoids followed after the synthetic routes for ∆9-THC established by Mechoulam and 
Gaoni in 1965. The first compounds initially synthesized were classical cannabinoids (i.e. 
analogs of ∆9-THC based on the dibenzopyran ring) including nabilone, levonantradol, and HU-
210 (Archer et al. 1977; Koe, 1981; Mechoulam et al. 1990). These compounds elicit similar 
discriminative stimulus properties compared to that of ∆9-THC in drug discrimination in both 
human and non-human animal models with relatively higher potencies (Young et al. 1981; Lile 
et al. 2010; Hruba et al. 2014). The first non-classical cannabinoids were those of the 
cyclohexylphenol (CP) series developed by Pfizer in the 1970s and 1980s as prototypical 
analgesics (Melvin et al. 1984; Compton et al. 1992). Notable examples include CP47,497, its 
C8 homologue (CP47,497-C8), and CP55,940. Synthetic hybrids exhibit structural features 
common to both classical and non-classical cannabinoids. AM-4030, an analog of HU-210 has 
both a dibenzopyran ring common among classical cannabinoids and an aliphatic hydroxyl group 
common among cyclohexylphenols, Aminoalkylindoles (AAIs) are structurally dissimilar from 
∆9-THC and classical synthetic cannabinoids and include compounds such as WIN55,212-2 and 
JWH-018, the first synthetic cannabinoid identified in smokable “spice” blends (Gatch & 
Forster, 2014). Eicosanoid synthetics were developed subsequent to the discovery of the 
endocannabinoids 2-AG and AEA. Compounds such as methanandamide and methylated 
fluoroanandamide (2-methylarachidonoyl-2’-fluoroanandamide) were developed for their 
increased metabolic stability compared to the putative endocannabinoids (Burkey & Nation, 
1997; Wiley et al. 1997). Eicosanoid derivatives have not been diverted towards abuse as other 
classes of synthetic cannabinoids and have largely been used to study the discriminative stimulus 
properties of the putative endocannabinoids 2-AG and AEA. As such they will be discussed with 
the endocannabinoids in the following subsection. Discrimination studies have demonstrated that 
synthetic cannabinoids dose-dependently substitute for ∆9-THC in both rodents and Rhesus 
monkeys and have ED50 values which correlate well with their CB1 receptor binding affinities 
(Compton et al. 1992; Gold et al. 1992; Lainton et al. 1995; McMahon et al. 2008; Järbe et al. 
2011; Ginsburg et al. 2012). Synthetic cannabinoids have been particularly useful in establishing 
structure activity relationships with respect to both in vitro and in vivo potencies (Wiley et al. 
1998; 2014). But given the limited therapeutic applications of cannabinoid agonists, drug 
discrimination has largely been used to assess abuse liability of novel cannabinoids.  
The first wave of abused synthetic cannabinoids included structural analogs of JWH-018 
(naphthoylindoles) such as JWH-073, JWH-203, JWH-204, and JWH-250 (Huffman et al. 2005; 
Wiley et al. 2012). These compounds have high affinity for CB1 receptors and produce full 
substitution in rodents trained to discriminate ∆9-THC via intraperitoneal administration as well 
as inhalation (Vann et al. 2009; Gatch & Forster, 2014; Marshell et al. 2014). JWH-018 
discrimination has been demonstrated in both rodents and Rhesus monkeys and has been the 
basis for studying the discriminative stimulus properties of XLR-11 and UR-144 which were 
derived from a series of tetramethylcyclopropyl ketone indoles developed by Abbot Laboratories 
(Uchiyama et al. 2013; Frost et al. 2008, 2010; Rodriguez et al. 2014; Wiley et al. 2014). Both 
XLR-11 and UR-144 showed dose-dependent substitution for ∆9-THC in mice and rats (Wiley et 
al. 2013; Gatch & Forster, 2015). Indazole cannabinoids have begun to replace naphthoylindole 
derivatives in products marketed for abuse. Indazoles which have been identified recently 
include AB-CHMINACA, AB-FUBINACA, and AB-PINACA all of which fully substitute in 
rodents trained to discriminate ∆9-THC from vehicle (Karinen et al. 2015; Shevyrin et al. 2014; 
Uchiyama et al. 2015; Wiley et al. 2015). As new synthetic cannabinoids infiltrate the gray 





Fig. 2.3 Chemical structures of the endogenous cannabinoids anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) (all structures drawn by author using ChemDraw Professional 
16.0. 1.4) 
 Initial attempts to train rodents to discriminate AEA failed and evaluation of substitution 
for ∆9-THC or CP55,940 showed mixed results. One study reported substitution in rats, but not 
in mice and only at dose which significantly reduced rate of responding (Wiley et al. 1995a). 
Other studies showed no substitution for ∆9-THC (Burkey & Nation, 1997; Wiley et al. 1998). 
Similarly, exogenous administration of AEA does not substitute for ∆9-THC in mice (Wiley et 
al. 2014). The rapid hydrolysis of AEA (Deutsch & Chin, 1993) accounted for the challenge to 
achieve consistent substitution of this endogenous ligand in drug discrimination studies. The 
rapid degradation of AEA was corroborated in subsequent studies showing enzymatic 
inactivation of the endocannabinoids (Boger et al. 2000; Dinh et al. 2002; Cravatt et al. 2002). 
Highly selective catabolic enzyme inhibitors would not become available until several years later 
and so investigators relied on metabolically stable analogs of AEA. These compounds were 
useful in establishing structure activity relationships to determine how the endocannabinoids, 
which are eicosanoid derivatives, interact with CB1 receptors in comparison to classical, non-
classical cannabinoids and their derivatives (Adams et al. 1995, 1998). Evaluation of their 
discriminative stimulus properties was also useful in exploring the physiological and behavioral 
roles of the endocannabinoids. 
The synthetic analog (R)-methanandamide substitutes for ∆9-THC but only in rats trained 
to discriminate a relatively lower training dose (3.0mg/kg or less) whereas no generalization 
occurs in rats trained to discriminate 5.6mg/kg or 30mg/kg (Burkey & Nation; 1997; Järbe et al. 
1998, 2000; Wiley et al. 2011). Explanations for these dissimilar substitution patterns include the 
possibility that higher dose (R)-methanandamide produces a discriminative stimulus via TRPV1 
receptors based on the observation (R)-methanandamide induces TRPV1-dependent locomotor 
depression (Millns et al. 2006). Another possibility is that ∆9-THC is more potent than (R)-
methanandamide. ∆9-THC is more potent than both O-1812 and methylated fluoroanandamide in 
mice trained to discriminate O-1812 and that it produces a higher degree of substitution than 
exogenous AEA in rats and monkeys trained to discriminate ∆9-THC (Wiley et al. 1997, 2004). 
Despite these differences in potency and receptor mechanisms, it is apparent that AEA shares 
CB1-dependent discriminative stimulus properties with ∆
9-THC considering that rimonabant 
completely attenuates substitution of (R)-methanandamide for ∆9-THC (Järbe et al. 2001). 
Analogs of AEA have also been used as the training drug in discrimination studies (Järbe et al. 
2001, 2009, 2010; Wiley et al. 2004, 2011). In rats trained to discriminate (R)-methanandamide 
from vehicle, AEA produced a higher degree of substitution than ∆9-THC. Of note, these results 
occurred when the interval between treatment and testing was reduced, reflecting 
pharmacokinetic differences, or when the training dose of methanandamide was sufficiently high 
that ∆9-THC yielded no substitution, indicating a CB1-independent mechanism (Järbe et al. 2001; 
Wiley et al. 2011).    
 Considering the differences between ∆9-THC and AEA or its analogs, genetic approaches 
have come into favor for studying the discriminative stimulus properties of endocannabinoids. 
Genetic deletion of FAAH or MAGL (i.e., FAAH(-/-) and MAGL(-/-) mice) results insignificantly 
elevated levels of AEA and 2-AG, respectively. This increased endocannabinoid tone imparts 
distinct phenotypes allowing researchers to study the implications of the endocannabinoid 
system in various physiological and behavioral processes such as metabolism, pain, and 
cognition (Lichtman et al. 2004; Petrenko et al. 2014; Kishimoto et al. 2015; Pan et al. 2011; 
Varvel et al. 2007; Tourino et al. 2010; Taschler et al. 2011). In particular, FAAH (-/-) mice have 
been trained to discriminate exogenously administered AEA from vehicle in two-lever and T-
maze procedures (Walentiny et al. 2011; Wiley et al. 2016). O-1812 was shown to substitute in 
both FAAH (-/-) and wildtype mice but was more potent in FAAH (-/-) mice suggesting that 
increased brain levels of AEA contributed to the discriminative stimulus effects of O-1812 
(Walentiny et al. 2015). So, in addition to pharmacological approaches using analogs of AEA, 
genetic deletion of FAAH has provided further evidence that the endocannabinoids similar to ∆9-
THC elicit their discriminative stimulus via CB1 receptor activation.  
 
 













Fig. 2.4 Chemical structures of selective and dual inhibitors of FAAH/MAGL (all structures 
drawn by author using ChemDraw Professional 16.0. 1.4) 
 Endocannabinoid discrimination studies focusing on AEA have used both 
pharmacological and genetic approaches to prevent its hydrolysis. It should be reasonable to 
predict that 2-AG has the similar discriminative stimulus properties as AEA given it too binds 
CB1 receptors with high affinity and is present in the CNS at concentrations up to 170 times that 
of AEA (Devane et al. 1992; Stella et al. 1997). SAR studies on the endocannabinoids have also 
revealed that the arachidonoyl acid moiety common to both AEA and 2-AG has the least amount 
of viable substitutions so the activity of either endocannabinoid at CB1 receptors would not be 
expected to differ greatly (Rabinovich and Ripatti, 1991; Rich, 1993). An approach to study the 
discriminative stimulus properties of 2-AG specifically is nevertheless required to make 
conclusions as to the role of either endocannabinoid in the subjective effects associated with CB1 
activation. Compared to FAAH (-/-) mice, MAGL (-/-) mice present certain confounders in that 
they exhibit reduced CB1 receptor expression and function as well as anxiety-like behaviors 
(Deng et al. 2020; Imperatore et al. 2015; Schlosburg et al. 2010). As such, MAGL(`-/-) mice 
have not been evaluated as FAAH(-/-) mice in discrimination studies but the development of 
selective and dual inhibitors of MAGL or FAAH has allowed investigators to study the 
discriminative stimulus properties of the primary endocannabinoid hydrolytic enzymes. Both 
MAGL and FAAH inhibitors induce large increases in levels of 2-AG and AEA in mouse brain, 
respectively which produces behavioral effects (Fegley et al. 2005; Anh et al. 2009; Long et al. 
2009; Chang et al. 2012; Niphakis et al. 2012, 2013).  
 
Monoacylglycerol Lipase (MAGL) Inhibitors  
 Similar to the case of AEA, exogenous 2-AG is rapidly degraded and fails to substitute 
for ∆9-THC (Matuszak et al. 2009; Wiley et al. 2014). Selective MAGL inhibitor JZL184 has 
been evaluated for discriminative stimulus effects and has been shown to partially substitute for 
∆9-THC in rodents (Wiley et al. 2014, 2016; Walentiny et al. 2015; Long et al. 2009). One study 
showed that mice receiving JZL184 produced no greater than 25% ∆9-THC appropriate 
responding although the rate of responding was reduced to less than that of vehicle (Hruba et al. 
2015). Other studies similarly have shown mixed results for selective MAGL inhibitors. KML29 
fails to substitute in mice trained to discriminate ∆9-THC from vehicle, suggesting that 
pharmacological blockade of MAGL alone is insufficient to produce subjective effects similar to 
∆9-THC (Ignatowska-Jankowska et al. 2014). MJN110 produces full substitution in mice trained 
on CP55,940 and interestingly JZL184 fully substitutes for CP55,940 whereas it had only 
partially substituted ∆9-THC in prior studies (Ignatowska-Jankowska et al. 2015).  
 
Fatty Acid Amide Hydrolase (FAAH) Inhibitors  
 The selective FAAH inhibitors URB-597 and PF-3845 do not substitute for ∆9-THC in 
rodent models of drug discrimination (Wiley et al. 2014; Hruba et al. 2015). URB-597 also fails 
to substitute for ∆9-THC in Rhesus monkeys (Stewart & McMahon, 2011). Putative AEA 
reuptake inhibitors AM-404 and UCM-707 similarly do not substitute for ∆9-THC in rodents 
(Solinas et al. 2007). Whereas these drugs are not sufficient to substitute for cannabinoids, 
combination of FAAH inhibitors and exogenous AEA produces behavioral effects. URB-597 and 
AEA produce full substitution for ∆9-THC in rats and Rhesus monkeys (Solinas et al. 2007; 
Stewart et al. 2011). In mice, PF-3845 in combination with AEA produces partial substitution up 
to 64% ∆9-THC lever responding (Wiley et al. 2014). These results suggest that elevating 
endogenous levels of AEA through FAAH inhibition are not high enough to produce subjective 
cannabinoid effects but FAAH blockade reveals the cannabinoid subjective effects of AEA.  
 
Dual MAGL & FAAH Inhibitors  
 Administration of the selective MAGL inhibitor JZL184 in FAAH (-/-) mice fully 
substitutes for ∆9-THC in food-reinforced discrimination procedures and partially substitutes in a 
water T-maze discrimination procedure (Walentiny et al. 2015; Long et al. 2009; Wiley et al. 
2016). JZL184 also partially substitutes for AEA in FAAH (-/-) mice in a water T-maze 
procedure. Similarly, the MAGL inhibitor KML29 produces full substitution for AEA in a food-
reinforced discrimination procedure (Ignatowska-Jankowska et al. 2014). Another method for 
endocannabinoid discrimination involves administration of both MAGL and FAAH inhibitors or 
a single dual FAAH/MAGL inhibitor in wildtype mice. The combination of PF-3845 and 
JZL184 produces full substitution for ∆9-THC in wildtype mice (Hruba et al. 2015). In the same 
study it was shown that another FAAH inhibitor URB-597 in combination with JZL184 resulted 
in mainly vehicle-lever responding. The disparate activities of PF-3845 and URB-597 in concert 
with JZL184 could be due to species differences as URB-597 and JZL184 co-administration in 
rats fully substitutes for ∆9-THC (Wiley et al. 2014). Dual FAAH/MAGL inhibitors JZL195 and 
SA-57 both fully substitute for ∆9-THC in wildtype mice trained to discriminate ∆9-THC from 
vehicle (Walentiny et al. 2015; Hruba et al. 2015; Long et al. 2009). SA-57 has also been used as 
a training drug in wild-type mice, exhibiting both dose- and time-dependent discriminative 
stimulus effects (Owens et al. 2016). Cross substitution was also demonstrated between SA-57 
and CP55,940 with either drug producing full substitution for the other in mice trained to 
discriminate SA-57 or CP55,940. SA-57 also produced full substitution for AEA in FAAH (-/-) 
mice, indicating involvement of 2-AG in producing a CB1-mediated discriminative stimulus. 
Taken together, the results from selective and dual inhibitors of FAAH and MAGL in both 
wildtype and FAAH (-/-) mice provide sufficient evidence to implicate both AEA and 2-AG as 
mediators of the cannabinoid discriminative stimulus in whole animals.   
 





Fig. 2.5 Chemical structures of CB1 receptor inverse agonists rimonabant and AM-251 (all 
structures drawn by author using ChemDraw Professional 16.0. 1.4) 
 
 The pharmacological properties of the CB1 receptor antagonist/inverse agonist 
rimonabant were first described in 1994 (Rinaldi-Carmona et al. 1994). In vitro, rimonabant 
antagonizes CB1 receptor agonist mediated inhibition of mouse vas deferens contraction and 
adenylyl cyclase activity. In vivo, rimonabant antagonizes the behavioral effects of CB1 receptor 
agonists in the mouse triad assay (three of the four measures in the tetrad assay excluding 
locomotor activity). Rimonabant was initially approved in the European Union as weight loss 
medication t for the treatment of obesity but was recalled due to its anxiogenic and depression 
side effects, as well as reports of suicide ideation, but was not approved in the U.S. (reviewed in 
Sam et al. 2011). Despite its failure as a therapeutic, rimonabant has proven invaluable to the 
study of cannabinoid pharmacology by providing insight into receptor mechanisms of action.  
With respect to cannabinoid drug discrimination, the discriminative stimulus effects of 
CB1 receptor agonists are considered CB1-dependent if rimonabant completely antagonizes their 
substitution under test conditions. Antagonism of the ∆9-THC discriminative stimulus has been 
demonstrated in numerous studies in several species including rodents, pigeons and monkeys 
(Wiley et al 1995c, d; Mansbach et al. 1996; Pério et al. 1996; Järbe et al. 2001, 2006; Solinas et 
al. 2004; McMahon et al. 2006; Walentiny et al. 2015). CB1 receptor antagonism with 
rimonabant was used to demonstrate that the discriminative stimulus effects of synthetic 
cannabinoids share the same CB1-dependent mechanism as ∆
9-THC (Wiley et al. 1995c, d, 2013; 
Pério et al. 1996; Järbe et al. 2001, 2006; DeVry & Jentzsch, 2004). The discriminative stimulus 
effects of the endocannabinoids were also proven to be CB1-dependent using rimonabant. 
Rimonabant reverses substitution of AEA in rats trained to discriminate methanandamide from 
vehicle (Järbe et al. 2001). The discriminative stimulus effects of both selective and dual 
FAAH/MAGL inhibitors in wildtype and FAAH (-/-) mice are also antagonized by rimonabant 
(Solinas et al. 2007; Walentiny et al. 2011, 2015; Wiley et al. 2016; Hruba et al. 2015; Stewart 
& McMahon, 2011; Long et al. 2009; Owens et al. 2016).  
Given anxiogenic effects of rimonabant in humans it would seem plausible that 
rimonabant alone may elicit a unique discriminative stimulus. However, attempts to establish 
rimonabant discrimination in pigeons and rats through food-reinforced discrimination procedures 
were unsuccessful (Mansbach et al. 1996; Pério et al. 1996). Rimonabant discrimination has 
been demonstrated in rats through a taste aversion paradigm in which lithium chloride was paired 
with rimonabant administration and not vehicle such that absence of the rimonabant 
discriminative stimulus served as cue to the rats that the solution was safe to drink (Järbe et al. 
2004, 2008). Rats on the same treatment schedule of rimonabant and vehicle without 
coadministration of lithium chloride did not demonstrate acquisition of the rimonabant cue. 
Substitution tests showed that AM-251, an analog of rimonabant fully substituted for rimonabant 
whereas the CB2 inverse agonists SR144528 and AM-630 failed to substitute indicating that the 
discriminative stimulus effects of rimonabant are CB1-mediated (Järbe et al. 2008). ∆
9-THC 
failed to substitute for rimonabant when given alone but when administered in combination with 
rimonabant, ∆9-THC attenuated rimonabant-induced taste aversion thereby demonstrating the 
opposing actions of CB1 receptor agonists and inverse agonists (Järbe et al. 2008).  
Shock avoidance in Rhesus monkeys receiving daily injections of ∆9-THC is another 
method for establishing rimonabant discrimination (McMahon & France 2003; McMahon, 
2006). Using this model, it has been shown that discontinuation of daily ∆9-THC injections 
induces rimonabant-lever responding with monkeys exhibiting overt behaviors indicative of 
cannabinoid withdrawal (Stewart & McMahon, 2010). Monkeys which did not receive daily 
injections of ∆9-THC did not acquire the rimonabant cue essentially making this version of 
rimonabant discrimination a precipitated withdrawal model. Consistent with this observation 
CB1 receptor inverse agonist AM-251 substitutes for rimonabant in Rhesus monkeys and 
pretreatment with CB1 receptor agonists including AEA, ∆
9-THC, CP55,940 and WIN55,212-2 
prior to the rimonabant training dose attenuates rimonabant-lever responding (McMahon, 2006; 
Stewart & McMahon, 2011).  
 Whereas rimonabant discrimination is difficult to establish under traditional procedures 
applied to CB1 agonists, discrimination of its analog O-6629 has been demonstrated in wildtype 
mice under FR10 food-reinforced conditions (Walentiny et al. 2013). Although O-6629 showed 
dose-dependent substitution for the training dose under test conditions it did not antagonize the 
discriminative stimulus of ∆9-THC in mice trained to discriminate ∆9-THC from vehicle and 
there was no cross-substitution between the two drugs in mice trained to discriminate either O-
6629 or ∆9-THC. Rimonabant also did not substitute for nor antagonize O-6629. The only drug 
which dose-dependently substituted for O-6629 was another pyrazole 3-substituent analog of 
rimonabant O-6658. These findings are consistent with another study which previously showed 
the series of analogs including O-6629 and O-6658 produced agonist-like effects in both 
wildtype and CB1
(-/-) mice which were not antagonized by rimonabant, suggesting this series 
represents a novel class of compounds with non-CB1 mediated mechanisms of action (Wiley et 
al. 2013).  
 










Fig. 2.6 Chemical structures of CB1 receptor allosteric modulators (all structures drawn by 
author using ChemDraw Professional 16.0. 1.4) 
 
Efforts to develop therapeutics which target the endocannabinoid system have largely 
focused on ligands which bind CB1 receptors at the orthosteric site (i.e. the principal site of 
action of CB1 receptor agonists) or which augment endocannabinoid tone through 
pharmacological blockade of FAAH and/or MAGL. Advances in functional screening of GPCR 
ligands in vitro has led to an increase in the availability of novel compounds which interact non-
competitively with orthosteric ligands through a distinct allosteric binding site (Rees et al. 
2002). Allosteric modulators may impart functional selectivity and/or biased signaling with 
respect to orthosteric ligands by inducing conformational changes of the receptor which alter 
certain parameters according to the extended ternary complex model for GPCRs (reviewed in 
Kenakin 2013, 2019). The first CB1 receptor allosteric modulators described were a series of 
compounds developed by Organon: Org27569, Org27759, and Org29647 (Price et al. 2005). 
Org27569 was shown to be a CB1 receptor negative allosteric modulator (NAM) in that it 
antagonized agonist-induced [35S] GTPS binding with significant decreases in the Emax values of 
CP55,940 and AEA (Price et al. 2005; Baillie et al. 2013). In vivo Org27569 decreased feeding 
behavior in rats and mice and attenuation of CP55,940-induced hypothermia in rats (Gamage et 
al. 2014; Ding et al. 2014). In drug discrimination however Org27569 did not alter the 
discriminative stimulus effects of ∆9-THC in C57BL6/J mice or AEA in FAAH (-/-) mice 
(Gamage et al. 2014). LDK1258, an analog of Org27569 similarly had no effect in drug 
discrimination when administered alone and neither altered the dose response curves for 
CP55,940 in C57BL6/J mice nor AEA in FAAH (-/-) mice (Mustafa, 2020). ZCZ011 has been 
well characterized as a CB1 receptor positive allosteric modulator (PAM) both in vitro and in 
vivo (Ignatowska-Jankowska et al. 2015). ZCZ011 displayed robust PAM activity in a battery of 
in vitro functional assays. In vivo ZCZ011 potentiated the pharmacological effects of CP55,940 
and AEA, showing significant increases in CP55,940-induced antinociception, catalepsy, and 
hypothermia in C57BL6/J mice as well as an increase in AEA-induced hypothermia in FAAH (-/-) 
mice. In drug discrimination ZCZ011 significantly increased the potency of both CP55,940 and 
AEA in C57BL6/J and FAAH (-/-) respectively without eliciting any discriminative stimulus 
effects or rate suppression when administered alone. ZCZ011 has garnered much interest in 
recent years primarily due to its antiallodynic effects in the chronic constriction injury (CCI) 
model of neuropathic pain which has spawned the development of analogs with similar 
antiallodynic activity including GAT211 and ABD1236 (Slivicki et al. 2018; Tseng et al. 2019). 
The discriminative stimulus effects of GAT211 and ABD1236 are not currently known.  
 
Future Directions in Cannabinoid Drug Discrimination  
 Cannabinoid discrimination has demonstrated several aspects of translation efficacy 
following its inception in the 1970s. Studies on ∆9-THC discrimination in several species 
provided convincing evidence for the existence of an endogenous cannabinoid receptor well 
before the development of in vitro assays to measure adenylyl cyclase activity the subsequent 
isolation and cloning of CB1 and CB2 receptors (Järbe et al. 1974; Devane et al. 1988, 1992; 
Matsuda et al. 1990; Munro et al. 1993). Following the development of synthetic CB1 receptor 
agonists drug discrimination found utility in assessment of abuse liability and in SAR studies 
which demonstrated correlation between CB1 receptor binding affinity and potency of 
discriminative stimulus effects in vivo (Compton et al. 1992; Gold et al. 1992; Lainton et al. 
1995; McMahon et al. 2008; Järbe et al. 2011; Ginsburg et al. 2012; Wiley et al. 1998; 2014; 
Gatch & Forster 2014, 2015). Reliable preclinical models for cannabimimetic activity such as 
drug discrimination were necessary in generating sufficient data to move CB1 receptor ligands to 
clinical trials in humans. Pharmaceutical formulations of ∆9-THC such as dronabinol have been 
approved by the FDA as an orexigenic for the treatment of cachexia in HIV/AIDS patients and as 
an antiemetic for the treatment chemotherapy-induced nausea and vomiting (Badowski, 2017; 
Wang et al. 2019). Discrimination studies involving FAAH and MAGL inhibitors were pivotal 
in characterizing the behavioral effects of the endocannabinoids and conversely showing that 
pharmacological blockade of these enzymes produces discernable behavioral effects. Correlation 
between discriminative stimulus effects of such compounds may be useful in identifying 
compounds with analgesic properties such as PF-3845 which reduces inflammatory pain and 
MJN110 which reduces neuropathic pain (Ahn et al. 2009; Ignatowska-Jankowska et al. 2015; 
Wilkerson et al. 2016). Drug discrimination remains a reliable measure of cannabimimetic side-
effects. Lastly, cannabinoid drug discrimination is useful assay to quantify CB1 receptor 
allosteric modulation. Considering the complex neural circuitry which mediates the 
discriminative stimulus effects of orthosteric CB1 receptor ligands, drug discrimination will be 
useful in examining whether allosteric modulator activity in vitro translates to behavioral effects 
in whole organisms. As such, drug discrimination may help identify novel compounds with 
useful properties such as ZCZ011, GAT211, and ABD1236 that are both potent and resistant to 
tolerance and dependence (Ignatowska-Jankowska et al. 2015; Slivicki et al 2018; Tseng et al. 
2019). Aside from potential use as analgesics CB1 receptor PAMs may also have utility in the 
treatment of cannabinoid use disorder (CUD) and substance use disorders involving non-
cannabinoid drugs of abuse (Trexler et al. 2019; Slivicki et al. 2020; Jing et al. 2014). 
 
 
Chapter 3: Divergent effects of ZCZ011 analogs in mouse models of 




 The rationale behind this study is to evaluate the 2-phenyl indole class of CB1 PAMs 
represented by ZCZ011 for antiallodynic effects in the CCI model of neuropathic pain, overt 
cannabimimetic effects in the tetrad assay, and subjective drug effects in the drug discrimination 
paradigm. Using the tetrad and drug discrimination assay we will test analogs of ZCZ011 for 
agonist activity alone and for PAM activity in combination with the orthosteric CB1 agonist 
CP55,940. Considering the activity of ZCZ011 analogs in CCI, tetrad, and drug discrimination 
we can examine the relationship between the antiallodynic effects, overt and subjective 
cannabimimetic effects of CB1 PAMs. Should any correlation exist between CCI and drug 
discrimination, then the drug discrimination paradigm may serve as a predictive model for 
antiallodynic activity of CB1 PAMs.  
Hypothesis 
 The tetrad and drug discrimination paradigms serve as predictive tools for the anti-
allodynic activity of CB1 PAMs in the CCI model of neuropathic pain. CB1 PAMs will produce 
no overt or subjective cannabimimetic effects when administered alone but will potentiate the in 
vivo pharmacological effects of the CB1 orthosteric agonist CP55,940. ZCZ011 and analogs, 
which behave as CB1 PAMs will show positive correlations between their potentiation of the 
pharmacological effects of CP55,940 in the triad and drug discrimination assays and their anti-
allodynic effects in the CCI model of neuropathic pain. 
Materials and Methods 
Drug Discrimination 
1. Subjects 
Twenty-four male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine, 
USA) were housed individually in clear plastic cages (18x29x30cm) with steel wire fitted 
tops and wood-chip bedding in a temperature controlled (20-22º C) vivarium. Training and 
test sessions were conducted at similar times during the light phase of a 12-hour light/dark 
cycle. Water was available ad libitum except during training and test sessions. Mice were 
maintained at 85-90% of free-feeding body weights by restricting daily rations of standard 
rodent chow (supplied by Harlan labs, Frederick, MD. Rodent diet 7912). Mice were given 
food ad libitum for a period of at least two weeks once every six months. Animals used in 
this study were cared for in accordance with the guidelines of the Institutional Animal Care 
and Use Committee of the Virginia Commonwealth University and the ‘Guide for the Care 
and Use of Laboratory Animals’ (National Research Council, 1996). 
2. Apparatus  
Experimental sessions were conducted in sound- and light-attenuated operant 
conditioning chambers (Med Associates, St. Albans, VT), Each chamber (18x18x18 cm) was 
equipped with a house light, two nose-poke apertures, and a recessed food receptacle 
centered between the apertures that was connected to a pellet hopper. Fans in the chambers 
provided ventilation and white noise. The house light remained off during training and test 
sessions. The chambers were connected to a computer running Med-PC software (Med 
Associates) used for scheduling contingencies and recording data. 
3. Procedures  
3.1. Overnight interactive FR training 
Mice were placed in designated operant chambers and trained to respond at one aperture 
according to a fixed ratio (FR) 1 schedule of reinforcement. A food pellet reinforcement was 
delivered after every response. After one hour or 50-100 reinforcements the FR value was 
increased to FR2 for the remainder of the overnight session. Overnight training was 
concluded after 10-12 hours and the aperture with the most responses for each mouse was 
designated as the preferred-side aperture.  
3.2. Interactive FR10 training 
Mice were placed in designated operant chambers and trained to respond at their 
preferred-side aperture at a FR2 schedule of reinforcement. The FR value was gradually 
increased to the final FR10 schedule of reinforcement in which 10 consecutive responses 
were required for delivery of food reinforcement. After mice were trained at one aperture, the 
contingency requirements were switched to the other aperture. Training at the second 
aperture proceeded identically to that at the first aperture. When responding at the second 
aperture under a FR10 schedule of reinforcement was acquired, discrimination training was 
initiated.  
3.3. Discrimination training 
Mice were trained to respond at one aperture following administration of 0.1 mg/kg 
CP55,940 s.c. (30-min pretreatment time) and to respond at the other lever following vehicle 
s.c. injection according to a FR10 schedule of reinforcement. Each response at the incorrect 
aperture reset the response requirement at the correct aperture. Daily injections were 
administered on a double alternation sequence of CP55,940 and vehicle (e.g. drug, drug, 
vehicle, vehicle). Daily 15-min training sessions were held until the mice had met three 
criteria during 9 of 10 consecutive training sessions: (1) the first completed FR10 (FFR) was 
at the correct aperture, (2) ≥80% of the total responding was at the correct aperture and (3) 
the rate of responding was ≥10min-1. When these criteria were met, acquisition of the 
discrimination was established, after which substitution and combination testing began.  
3.4. Substitution and Combination tests 
Discrimination training was continued 5-7 days per week with stimulus substitution or 
combination tests occurring up to two days per week with no less than 72 hours between 
tests. To be eligible for testing, mice must have passed discrimination criteria during their 
last drug and vehicle training sessions. Prior to substitution or combination tests, 
generalization curves for CP55,940 were generated for all mice. During test sessions, 
responses at either aperture delivered reinforcement according to an FR10 schedule. 
Substitution and combination tests were conducted with several 2-phenyl indole analogs of 
ZCZ011 including GAT211, LDK1747, and LDK1752. For substitution tests, the test 
compound (40 mg/kg) or vehicle i.p. was administered 30-min prior to the test session. For 
combination tests, the test compound (40 mg/kg) or vehicle i.p. was administered 15-min 
prior to treatment with CP55,940 (0.01, 0.03, 0.056, 0.1, 0.3, or 1.0 mg/kg) or vehicle s.c. 
and 45-min prior to the test session. To ensure maintenance of CP55,940’s discriminative 
stimulus effects, control tests with the training dose of CP55,940 and vehicle were repeated 
before conducting substitution or combination tests with novel compounds.  
4. Drugs 
ZCZ011 and its analogs have been previously characterized in vitro with CP55,940 
(Table 1.1). Therefore CP55,940 will serve as the orthosteric probe for the present studies. 
CP55,940 was supplied by the National Institute on Drug Abuse (NIDA). GAT211, 
LDK1747, and LDK1752 were synthesized at the Rangel College of Pharmacy Health 
Science Center at Texas A&M University (Kingsville, TX, USA). Drugs were dissolved via 
sonication in a vehicle consisting of ethanol, Alkamuls-620 (Sanofi-Aventis) and saline in a 
ratio of 1:1:18. All drugs were administered at an injection volume of 10𝜇l per gram of body 
mass. Subcutaneous route of administration was used for CP55,940 and vehicle injections in 
the drug discrimination studies. Intraperitoneal route of administration was used for all other 
drugs. 
5. Dose selection 
ZCZ011 and all analogs were tested at a dose of 40 mg/kg in the drug discrimination, 
tetrad, and CCI experiments. ZCZ011 is analgesic in the CCI model at 40 mg/kg and so 
that dose will serve as the basis for comparison for ZCZ011 analogs. 
6. Data analysis 
Acquisition indices were the percentage of animals meeting the discrimination training 
criteria (1.3.3). For each test session, the percentage of responses at the drug-side aperture 
and response rate (responses/min) were calculated. Mice that responded less than 10 times 
during a test session did not receive a reinforcement and so were excluded from analysis of 
aperture selection. All mice were included in analysis of response rate. Full substitution for 
CP55,940 was defined as ≥80% CP55,940-appropriate responding. Partial substitution for 
CP55,940 was defined as ≥20% and <80% CP55,940-appropriate responding.  
Tetrad  
1. Subjects 
12 Male and female C57BL/6J mice (Jackson Laboratory, Bar Harbor, Maine, 
USA) were housed in clear plastic cages (18x29x30cm) with steel wire fitted tops and 
wood-chip bedding in a temperature controlled (20-22º C) vivarium. Food and water 
were available ad libitum. Mice were tested during the day on a normal 12-hour light-
dark cycle. Animals used in this study were cared for in accordance with the guidelines of 
the Institutional Animal Care and Use Committee of the Virginia Commonwealth 
University and the ‘Guide for the Care and Use of Laboratory Animals’ (National 
Research Council, 1996). 
2. Procedures 
2.1. Baseline measurements 
Prior to injection, mice were weighed and baseline measurements were taken of 
tail withdrawal latency and rectal temperature. Mice were injected following baseline 
measurements and then tested 30-min later in the order which follows. 
2.2. Locomotor activity assessment 
Locomotor effects were assessed by placing mice in clear Plexiglas enclosures 
(43x21x20 cm) housed in sound- and light-attenuated chambers equipped with a house 
light and Fire-i™ digital cameras (Unibrain, San Ramon, CA, USA). Fans in the 
chambers provided ventilation and white noise. The house light remained on during the 
300 second test sessions. The chambers were connected to a computer running Anymaze 
(Stoelting, Wood Dale, IL) software for session parameter control and data collection. 
Distance traveled (m), time immobile (s), and mean speed were recorded over 300 
seconds.  
2.3. Catalepsy bar test 
Catalepsy was assessed on a metal bar attached to a ring-stand placed 4.5 cm 
above the platform. The mice were placed with their front paws resting on the bar and 
time spent immobile was measured over 60 seconds. If the mouse climbed onto the bar 
or moved from its fixed position it was replaced for a maximum of three tries.  
2.4. Warm-water tail withdrawal assay 
Thermal nociceptive behavior was assessed by immersing the distal portion 
(approximately 1 cm) of the mice tails in a water bath held at 52º C. Tail withdrawal 
latency was measured up to a maximum of 10 seconds. Data were expressed as percent 
change from baseline or maximum percent effect (%MPE) according to the formula: 
%MPE = [(test latency – preinjection latency) / (10 – preinjection latency)] ×100. 
2.5. Rectal temperature 
Hypothermic effects were assessed by measuring rectal temperature with a 
thermometer probe (Physitemp Instruments, Clifton, NJ) inserted 2 cm into the rectum. 
Data were expressed as a change in temperature (ΔT) from baseline measured in ºC. 
3. Drugs 
See Drug Discrimination section 4.0 
4. Dose selection 
See Drug Discrimination section 5.0 
 
Chronic Constriction Injury (CCI) Model of Neuropathic Pain  
1. Subjects  
See Tetrad section 2.1 
2. Apparatus 
Mice were placed individually in Plexiglas cylinders (8 cm diameter, 15 cm 
height) situated over a wire screen mesh surface. A blanket was draped over the setup to 
blind mice to visual distractions in the laboratory. Mice were observed from below the 
surface of the screen mesh.  
3. Procedures 
3.1. Sciatic nerve ligation 
Surgery was performed according to techniques described previously (Bennett & 
Xie et al. 1988; Ignatowska-Jankowska et al. 2015). Mice were anesthetized with 
isoflurane and the surgical site was prepared using aseptic technique. The sciatic nerve 
was isolated and loosely ligated. The sham surgery was performed identically but 
without nerve ligation.  
3.2. Von Frey test for mechanical hypersensitivity 
Mechanical hypersensitivity following surgery was measured using von Frey 
calibrated filaments as previously described (Murphy et al. 1999). Von Frey filaments 
were applied to the hind paws ipsilateral and contralateral to the surgery at 30-min 
postinjection. The stimulus threshold which evoked a response as defined by either 
lifting, licking, or shaking of the paw was recorded. 
4. Drugs 
See Drug Discrimination section 4.0 
5. Dose selection 




Evaluation of ZCZ011 analogs in the tetrad assay 
The tetrad assay was performed in a series of four experiments (detailed in section 2.2). 
ZCZ011 analogs did not elicit full cannabimimetic effects in the tetrad assay. LDK1729 (40 
mg/kg) suppressed locomotor activity with respect to distance traveled and time spent immobile 
(p < 0.01; unpaired t-test) (Table 3.1) and showed small but significant hypothermic effects at 30 
min post-administration (F (2, 20) = 9.292; P = 0.001). However, LDK1729 (40 mg/kg) did not 
produce significant cataleptic or antinociceptive effects. The remaining analogs (ZCZ011, 
ABD1236, GAT211, LDK1730, LDK1747, LDK1750, LDK1752) did not produce significant 
effects in any of the tetrad measures (Table 3.1).  
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(*) indicates significant results 
 
Acquisition and discrimination of the CP55,940 discriminative stimulus shows no sex differences 
Cannabinoid drug discrimination studies in rodents have traditionally used male subjects. 
Therefore, the first set of experiments examined whether there were sex differences in 
acquisition of CP55,940 discrimination. Discrimination acquisition curves were constructed for 
male and female C57BL/6J mice training to discriminate CP55,940 (0.1 mg/kg) from vehicle 
(Fig. 3.1A). All mice acquired the discriminative stimulus of CP55,940 (0.1 mg/kg) within 90 
training days. Unpaired t-test of male and female learning curves (Fig. 3.1B) showed no 
significant difference in acquisition according to sex (t=1.613). Dose-response curves for 
responding on the CP55,940 associated aperture and response rates were constructed using 
CP55,940 (0.01-1.0 mg/kg). Responding on the drug aperture was statistically significant at 0.1 
mg/kg (CP55,940 main effect: F (DFn, DFd) 3.668 (5, 95); P < 0.0001; Fig. 3.1C). Rate of 
responding was significantly decreased at and above 0.3 mg/kg (CP55,940 main effect: F (DFn, 
DFd) 8.685 (5, 122); P <0.0001; Fig. 3.1E). The data were also plotted according to sex (Fig. 
3.1D, F) and analyzed using two-way ANOVA. No significant difference was observed between 
males and females for CP55,940 drug-like responding or response rates (interaction between sex 
and dose: F (5, 90) = 0.5777, P = 0.7169; CP55,940 main effect: F (5, 90) = 32.19, P < 0.0001; 















Figure 3.1 Male and female C57BL6/J mice show identical acquisition rates of CP55,940 in the drug 
discrimination paradigm similar generalization curves of CP55,940 (A) Discrimination learning curve shows 
100% of total C57BL/6J mice acquired the discriminative stimulus of CP55,940 within 90 training days. (B) 
Discrimination learning curve for males and females reveal no sex differences for acquisition of the CP55,940 
discriminative stimulus. (C) CP55,940 (0.01-1.0 mg/kg) produces a dose-dependent discriminative stimulus in 
C57/BL6J mice. (D) No sex differences exist for CP55,940 (0.01-1.0 mg/kg) drug-like responding (E) CP55,940 
(0.01-1.0 mg/kg) produces dose-dependent suppression of response rates in C57BL6/J mice. (F) No sex 
differences exist for CP55,940 (0.01-1.0 mg/kg) effect on response rates. N = 23 C57BL6/J mice; n = 11-12 mice 
per sex. All data were collected 30 min after treatment administration and reported as mean ± SEM. Data were 
analyzed via unpaired t-test (B), one-way ANOVA (C) & (D), or two-way ANOVA (D) & (F). 
 
 
Evaluation of GAT211, LDK1747, and LDK1752 substitution for CP55,940 in the drug 
discrimination paradigm  
ZCZ011 analogs were screened for subjective cannabimimetic effects by measuring 
substitution for the discriminative stimulus of CP55,940 (0.1 mg/kg) in the drug discrimination 
paradigm. GAT211 (20-40 mg/kg) did not substitute for CP55,940 (0.1 mg/kg) and had no effect 
on response rates at 30 min post-injection (Fig 3.2A). LDK1747 (40 mg/kg) did not substitute for 
the discriminative stimulus of CP55,940 (0.1 mg/kg) and had no effect on response rates at 45 
min post-injection (Fig. 3.2B). LDK1752 (40 mg/kg) did not substitute for CP55,940 (0.1 mg/kg) 








Figure 3.2 Evaluation of GAT211, LDK1747, and LDK1752 substitution for CP55,940 in the drug discrimination 
paradigm. (A) GAT211 (20 or 40 mg/kg) did not substitute for the discriminative stimulus of CP55,940 (0.1 
mg/kg) and did not suppress the rate of responding. (B) LDK1747 (40 mg/kg) did not substitute for the 
discriminative stimulus of CP55,940 (0.1 mg/kg) and did not alter the rate of responding. (C) LDK1752 did not 
substitute for the discriminative stimulus of CP55,940 (0.1 mg/kg) and did not alter the rate of responding. All 
data were collected 30 min after treatment and reported as mean ± SEM. All data were analyzed using one-way 
ANOVA.  
Evaluation of ZCZ011 analogs in augmenting the pharmacological effects of CP55,940:  triad 
assay  
 ZCZ011 analogs were tested in combination with CP55,940 in the triad assay to screen 
for allosteric modulator effects. ZCZ011 (40 mg/kg) potentiated the cataleptic, antinociceptive, 
and hypothermic effects of CP55,940 (0.3 mg/kg) (Fig. 3.3A). ABD1236 (40 mg/kg) potentiated 
CP55,940-induced antinociception and hypothermia (Fig. 3.3B). GAT211 (20-40 mg/kg) 
potentiated CP55,940-induced catalepsy, antinociception, and hypothermia (Fig. 3.3C). 
LDK1729 (40 mg/kg) potentiates CP55,940-induced hypothermia (Fig. 3.3D). LDK1730 slightly 
potentiated CP55,940-induced hypothermia with significance at 1.0 mg/kg CP55,940 (Fig. 3.3E) 
LDK1747 (40 mg/kg) potentiated CP55,940-induced antinociception and hypothermia (Fig. 
3.3F). LDK1750 (40 mg/kg) does not affect the dose-effect relationships of CP55,940 (Fig. 
3.3G). LDK1752 (40 mg/kg) produced a small but significant potentiation of CP55,940-induced 
catalepsy (F (3, 30) = 4.013; P <0.0001; Fig. 3.3H), but only at 0.3 mg/kg CP55,940. LDK1752 
(40 mg/kg) failed to alter the dose-response relationships of CP55,940 (0.1-3.0 mg/kg) for 
antinociception and hypothermia (Fig. 3.3H). The ED50 values of CP55,940 as well as potency 
ratios were calculated for each measure of the triad assay. Table 3.2 shows the ED50 and potency 



































Figure 3.3 Evaluation of ZCZ011 analogs in combination with CP55,940 in the triad assay. (A) ZCZ011 (40 
mg/kg) potentiates CP55,940-induced catalepsy, antinociception, and hypothermia. (B) ABD1236 (40 mg/kg) 
potentiates CP55,940-induced antinociception and hypothermia. (C) GAT211 (20-40 mg/kg) potentiates 
CP55,940-induced catalepsy, antinociception, and hypothermia. (D) LDK1729 (40 mg/kg) slightly potentiated 
CP55,940-induced antinociception. (E) LDK1730 (40 mg/kg) slightly potentiated CP55,940 induced hypothermia 
(F) LDK1747 (40 mg/kg) potentiates CP55,940-induced antinociception and hypothermia. (G) LDK1750 (40 
mg/kg) does not affect the dose-effect relationships of CP55,940. (H) LDK1752 (40 mg/kg) slightly potentiated 
CP55,940-induced catalepsy with significance at 0.3 mg/kg dose of CP55,940 but did not alter the antinociceptive 
or hypothermic effects of CP55,940 (0.1-3.0 mg/kg). All data are reported as mean ± SEM and were analyzed via 
two-way ANOVA. Experiments (A-G) conducted by Julien Dodu and Mohammed Mustafa.  
 
Table 3.2 Effects of ZCZ011 analogs on CP55,940 ED50  and potency ratio values in the triad assay  
  
ED50 (CL 95%) CP55,940 (mg/kg) Potency Ratio (CL 95%) 
Compound Measure Vehicle PAM 
 
ZCZ011 catalepsy 0.55 (0.36-0.85) 0.31 (0.21-0.46) 1.66 (0.95-3.17) 
antinociception 0.42 (0.29-0.63) 0.30 (0.21-0.42) 1.40 (0.84-2.48) 
hypothermia 1.19 (0.93-1.53) 0.44 (0.35-0.55) 2.08 (1.38-3.36) 
ABD1236 catalepsy 0.36 (0.28-0.46) 0.41 (0.31-0.55 0.89 (0.65-1.22) 
antinociception 0.58 (0.40-0.84) 0.18 (0.12-0.27) 3.26 (1.77-8.49) 
hypothermia 0.35 (0.31-0.41) 0.22 (0.18-0.27) 1.57 (1.23-2.04) 
GAT211 catalepsy 0.53 (0.34-0.84) 0.47 (0.26-0.83) 1.12 (0.77-1.64) 
antinociception 0.57 (0.42-0.79) 0.21 (0.17-0.27) 2.48 (1.63-4.03) 
hypothermia 0.33 (0.27-0.39) 0.14 (0.12-0.18) 1.87 (1.45-2.45) 
LDK1729 catalepsy 0.53 (0.37-0.78) 0.48 (0.33-0.71) 1.15 (0.72-1.86) 
antinociception 0.44 (0.28-0.51) 0.38 (0.28-0.51) 1.16 (1.01-1.33) 
hypothermia 0.29 (0.23-0.37) 0.18 (0.14-0.24) 1.54 (1.17-2.04) 
LDK1730 catalepsy 0.33 (0.19-0.58) 0.43 (0.21-0.87) 0.88 (0.33-2.32) 
 
antinociception 0.13 (0.05-0.36 0.18 (0.06-0.51) 0.71 (0.15-3.32) 
 
hypothermia 0.33 (0.21-0.52) 0.14 (0.10-0.19) 2.31 (1.41-3.86) 
LDK1747 catalepsy 0.28 (0.21-0.37) 0.21 (0.14-0.31) 1.32 (0.84-2.11) 
antinociception 0.40 (0.30-0.55) 0.33 (0.24-0.44) 1.25 (0.89-1.77) 
hypothermia 0.26 (0.22-0.31) 0.16 (0.13-0.19) 1.58 (1.35-1.84) 
LDK1750 catalepsy 0.32 (0.17-0.60) 0.63 (0.38-1.09) 1.80 (0.71-4.94) 
antinociception 0.07 (0.04-0.14) 0.04 (0.02-0.09) 0.78 (0.24-2.49) 
hypothermia 0.13 (0.09-0.18) 0.13 (0.10-0.16) 0.98 (0.67) 
LDK1752 catalepsy 0.53 (0.29-0.96) 0.35 (0.13-0.91) 0.56 (0.31-1.00) 
antinociception 0.48 (0.38-0.61) 0.40 (0.31-0.51) 0.82 (0.60-1.13) 
hypothermia 0.36 (0.28-0.46) 0.32 (0.25-0.40) 0.85 (0.60-1.19) 
 
 
Evaluation of GAT211, LDK1747, and LDK1752 in combination with CP55,940 in the drug 
discrimination paradigm  
 In the combination studies, GAT211 (40 mg/kg) did not alter the dose-response 
relationship of CP55,940 (0.01-1.0 mg/kg) in drug-like responding or response rates at 45 min 
post-injection (Fig. 3.4A, B). Separate analysis of male and female data using 2-way ANOVA 
showed no significant difference in drug-like responding (Table 3.3) or response rates (Table 
3.4) following GAT211 (40 mg/kg) administration. LDK1747 (40 mg/kg) did not alter the dose-
response relationship of CP55,940 (0.01-1.0 mg/kg) in drug-like responding or response rates at 
45 min post-injection (Fig. 3.4C, D). Separate analysis of male and female data using 2-way 
ANOVA showed no significant difference in drug-like responding (Table 3.3) or response rates 
(Table 3.4) following LDK1747 (40 mg/kg) administration. LDK1752 (40 mg/kg) slightly 
potentiated the discriminative stimulus of CP55,940 with significance at 0.03 mg/kg (interaction 
between LDK1752 and CP55,940: F (2, 10) = 6.486, P = 0.0156; CP55,940 main effect: F (2, 
10) = 26.64, P < 0.0001; LDK1752 main effect: F (1, 5) = 5.673, P = 0.0630; Fig. 3.4E). 
LDK1752 (40 mg/kg) did not alter the dose-response relationship of CP55,940 with respect to 
response rates (Fig. 3.4F). Separate analysis of male and female data using 2-way ANOVA 
showed no significant difference in drug-like responding (Table 3.4) or response rates (Table 









Figure 3.4 Evaluation of GAT211, LDK1747, and LDK1752 in combination with CP55,940 in the drug 
discrimination paradigm. (A) GAT211 (40 mg/kg) did not alter the dose-response curve of CP55,940 drug-like 
responding (B) GAT211 (40 mg/kg) did not alter the dose-response curve of CP55,940 rate of responding. (C) 
LDK1747 (40 mg/kg) did not alter the dose-response curve of CP55,940 drug-like responding (D) LDK1747 (40 
mg/kg) did not alter the dose-response curve of CP55,940 rate of responding. (E) LDK1752 potentiated CP55,940 
drug-like responding with significance at 0.03 mg/kg (F) LDK1752 (40 mg/kg) did not alter the dose-response 
curve of CP55,940 (0.01-1.0 mg/kg) in rate of responding.  
 
Table 3.3 Summary of two-way ANOVA between sex and allosteric pretreatment in drug-like responding 
 




















GAT211 5, 17 = 
1.123 




**** 1, 17 = 
0.7499 
0.7499 ns 
LDK1747 4, 8 = 
0.1930 
0.9353 ns 4, 8 = 
12.38 
0.0017 ** 1, 2 = 
0.01468 
0.9146 ns 
LDK1752 2, 4 = 
0.0869 
0.9185 ns 2, 4 = 
18.53 




Table 3.4 Summary of two-way ANOVA between sex and allosteric pretreatment in rate of responding 
 




















GAT211 6, 21 = 
1.397 




**** 1, 21 = 
0.08988 
0.7673 ns 
LDK1747 6, 12 = 
0.8609 
0.5495 ns 6, 12 = 
6.184 
0.0037 ** 1, 2 = 
1.775 
0.3143 ns 
LDK1752 6, 12 = 
1.111 
0.4107 ns 6, 12 = 
7.358 




Evaluation of ZCZ011 analogs in the chronic constriction injury (CCI) model of neuropathic 
pain 
The ZCZ011 analogs, ABD1236, GAT211, LDK1729, LDK1730, LDK1747, LDK1750, 
and LDK1752 (Fig. 3.5) were evaluated in the CCI model of neuropathic pain. ZCZ011, 
ABD1236, and GAT211 produced full reversal of allodynia, whereas the LDK series of 
compounds lacked activity. ZCZ011 (40 mg/kg) produces time-dependent reversal of allodynia 
for up to twelve hours following administration and this effect is not subject to tolerance under 
repeated administration (Fig. 3.6A). ABD1236 (40 mg/kg) produces significant increases in paw 
withdrawal thresholds for up to four hours post-administration (Fig. 3.5). GAT211 (40 mg/kg) 
was shown to reverse allodynia for up to eight hours following administration (Fig. 3.5). The 
remaining analogs LDK1729, LDK1730, LDK1747, LDK1750, and LDK1752 at 40 mg/kg had 












































Figure 3.5 Evaluation of ZCZ011 analogs in the CCI model of neuropathic pain. (A) ZCZ011 (40 mg/kg) 
reverses allodynia up to 12 hours post administration and maintains its effect following repeated administration. 
(B) ABD1236 (40 mg/kg) reverses allodynia up to 4 hours post administration. (C) GAT211 (40 mg/kg) reverses 
allodynia up to 8 hours post administration. (D-H) LDK series of ZCZ011 analogs fail to reverse allodynia at a 
dose of 40 mg/kg. n = 6-8 C57BL6/J mice per treatment group; mixed sex. All data are reported as mean ± SEM. 
Surgeries and experiments conducted by Lauren Moncayo and Rebecca Moncayo.  
 
  
Chapter 4. Discussion and Conclusions   
 
Summary of Results  
The results obtained from studies on GAT211, LDK1747 and LDK1752 are summarized 
along with those of previous in vivo experiments on ZCZ011 and its analogs in Table 4.1. 
Almost no activity was seen for any compound in the tetrad assay except for minor locomotor 
suppression and hypothermic effects following LDK1729 administration. In the triad assay, only 
ZCZ011 and GAT211 produced leftward shifts in the dose-response relationship of CP55,940 for 
all three measures. ABD1236 and LDK1747 did not alter the cataleptic effects of CP55,940. 
LDK1729 and LDK1730 potentiated only hypothermic effects of CP55,940, whereas LDK1752 
potentiated catalepsy, only. ZCZ011 was the only 2-phenyl indole characterized in drug 
discrimination prior to this study. This study examined GAT211, LDK1747, and LDK1752 in 
the drug discrimination paradigm. ZCZ011 analogs all failed to substitute for the discriminative 
stimulus of CP55,940 and had no effect on response rates. In the combination studies, only 
ZCZ011 and LDK1752 potentiated the discriminative stimulus effects of CP55,940 and none of 
the compounds had any effect on response rates. In the CCI model of neuropathic pain, only 
ZCZ011, ABD1236, and GAT211 had antiallodynic activity whereas the LDK series of 
compounds were ineffective. In summary, ZCZ011 is the only 2-phenyl indole, which elicits 
leftwards shifts in the CP55,940 dose response relationships in the triad assay and drug 





Compound CCI Model of 
Neuropathic Paina 
Tetradb Triadc [CP55,940] Drug Discriminationd 




ABD1236 potentiation (2/3); no 
effect on catalepsy  
not tested 
GAT211 potentiation (3/3) no substitution or rate 
suppression 
 
no effect on CP55,940 dose 
response  













no effect potentiation (2/3); no 
effect on catalepsy  
no substitution or rate 
suppression 
 




no effect potentiates catalepsy no substitution or rate 
suppression 
 
potentiates DLR% without 
effect on response rates 
a. Surgeries and experiments conducted by Lauren Moncayo and Rebecca Moncayo. 
b. (c) (d) Experiments conducted by Julien Dodu and Mohammad Mustafa. GAT211, LDK1747, and 
LDK1752 studies were conducted by the author. 
 
In Vivo activity of ZC011 analogs   
Before interpreting the results, the rationale behind dose selection and use of male and 
female subjects in the drug discrimination paradigm should be discussed. The dose chosen for 
each CB1 PAM evaluated was based on the effective dose of ZCZ011 in previous studies that 
produced full reversal of allodynia in the CCI model (i.e., 40 mg/kg; i.p.) (Ignatowska-
Jankowska et al. 2015). At this dose, ZCZ011 also produced leftward shifts in the dose-response 
curves of CP55,940 in the triad assay and drug discrimination paradigm and so this parent 
compound was considered the gold standard by which to compare the other analogs. Therefore, 
should an analog not exhibit the same degree of PAM activity in vivo as ZCZ011, one could test 
a higher dose but having to do so would mean the same compound has no therapeutic advantage 
over ZCZ011. Furthermore, solubility presents more of a challenge when preparing doses greater 
than 40 mg/kg. Drug discrimination studies have largely used only male subjects however sex 
differences in subjective responses to cannabinoids have been demonstrated in humans and 
rodents. In humans, females have reported greater subjective responses to ∆9-THC at 3 mg (p.o.) 
than males, whereas males reported greater sensitivity at higher doses of ∆9-THC (15 mg/kg p.o.) 
(Fogel et al. 2017). Female Sprague-Dawley rats learn to discriminate ∆9-THC faster and at 
lower doses (1 mg/kg vs 3 mg/kg) than their male counterparts (Wiley et al. 2017). One study 
using C57BL6/J trained to discriminate ∆9-THC (0.56 mg/kg) for food reinforcement showed 
that CP55,940 was more potent in male subjects than in females (Wiley et al. 2019). Therefore, it 
was important to evaluate sex differences in the cannabinoid discrimination paradigm used in 
this study. Here, we report that the potency of the CP55,940 discriminative stimulus did not 
differ between male and female C57BL6/J mice and response rates similarly showed no 
differences (Table 4.1). 
 
ZCZ011 analogs do not elicit overt or subjective cannabimimetic effects 
 The purpose of the tetrad assay was to screen ZCZ011 analogs for CB1 agonist-mediated 
cannabimimetic effects. Consistent with the assertion that PAMs do not activate the orthosteric 
site of their respective receptors, ZCZ011 analogs do not elicit the full tetrad set of behavioral 
effects seen with CB1 agonists. LDK1729 elicited only minor locomotor and hypothermic effects 
and lacked activity in the other behavioral measures. The drug discrimination paradigm was used 
to screen ZCZ011 analogs for discriminative stimulus effects similar to CP559,940. When tested 
for substitution, none of the ZCZ011 analogs substituted for the discriminative stimulus of 
CP55,940 (0.1 mg/kg). Accordingly, ZCZ011 analogs do elicit in vivo pharmacological effects 
associated with CB1 orthosteric agonists. These results seem consistent with the activity of 
ZCZ011 analogs in vitro. The Emax values for ZCZ011 analogs with respect to cAMP-inhibition 
and ß-arrestin recruitment would indicate these compounds have some agonist activity, however 
their EC50 values are orders of magnitude higher in comparison to CP55,940 (Table 1.1). 
ZCZ011 analogs are then considerably lacking in potency at the orthosteric site of CB1 receptors 
compared to direct agonists both in vitro and in vivo, as would be expected for purported CB1 
PAMs. Whether any ZCZ011 analog acts at the orthosteric site or functions as an allosteric 
agonist at CB1 receptors in vitro, it is not behaviorally relevant as cannabimimetic effects were 
not observed in the tetrad assay or substitution tests.  
 
Activity comparisons between ZCZ011 analogs across behavioral paradigms 
The overall purpose of this study was to examine the relationship between the 
antiallodynic, overt and subjective cannabimimetic effects of CB1 PAMs represented by 
ZCZ011. According to the hypothesis, antiallodynic analogs of ZCZ011 should have also elicited 
leftward shifts of the CP55,940 dose-response curves in the tetrad assay and drug discrimination 
paradigm. In other words, positive allosteric modulation of the overt and subjective effects of 
cannabinoids was expected to be positively associated with reversal of allodynia in the CCI 
model of neuropathic pain. The data from this study did not suggest a relationship among the 
CCI, tetrad, and drug discrimination paradigms for CB1 PAMs.  
On the other hand, three compounds that produced antinociception in the CCI assay also 
augmented the pharmacological effects of CP55,940 in the triad assay. In the triad assay, 
ZCZ011, ABD1236, and GAT211 had in general greater effects on CP55,940 potency than the 
LDK series. LDK1747, similar to ABD1236, potentiated CP55,940-induced antinociception and 
hypothermia however LDK1747 was less potent by comparison. These results suggest that CB1 
PAMs, which augment the overt cannabimimetic effects of CP55,940 in the triad assay, may be 
predictive of antinociceptive activity in the CCI model of neuropathic pain. However, this 
relationship does not extend to the drug discrimination paradigm. GAT211 which has been 
shown to produce antiallodynic effects in a CIPN model of neuropathic pain at a dose of 20 
mg/kg (Slivicki et al 2018) did not potentiate the discriminative stimulus effects of CP55,940 
and also had no effect on response rates even at 40 mg/kg. As expected for CB1 PAMs, neither 
GAT211, LDK1747, nor LDK1752 substituted for the discriminative stimulus of CP55,940. Of 
these compounds only LDK1752 potentiated the CP55,940 discriminative stimulus. This result 
was surprising considering LDK1752 had only a minor effect in the triad assay and lacked any 
effects in CCI or the tetrad assay. Additionally, GAT211 which behaved as a PAM in the triad 
assay failed to do so in drug discrimination. Taken together, these results suggest that 
antiallodynic activity in CCI is not correlated with PAM activity in the triad assay and drug 
discrimination paradigm.  
The disparate effects of ZCZ011 analogs in vivo merits discussion on the separate 
neurological mechanisms which govern the behaviors each measured in CCI, tetrad, and drug 
discrimination. The CCI model and tail-flick test of the tetrad assay are both measures of pain 
and so both involve pathways mediating pain transmission and modulation. The drug 
discrimination paradigm, however, is a measure of subjective drug effects and is performed in 
the absence of painful stimuli. The discriminative stimulus effects of a drug involve a 
combination of sensory and affective components, either of which can be modulated to produce 
antinociception. Whether the antiallodynic or antinociceptive properties of a drug depends more 
on its modulation of the sensory or affective components of pain may also affect its 
discriminative stimulus properties. That is to say selective modulation of pathways mediating the 
sensory or affective components of pain may explain why antiallodynic analogs of ZCZ011 such 
as GAT211 have no effect in the drug discrimination paradigm. Additionally, it is known that 
models of neuropathic pain can lead to phenotypic alterations in CB1 receptor and 
endocannabinoid levels (Ignatowska-Jankowska et al. 2015; Petrosino et al. 2007; Siegling et al. 
2001). Therefore, it is possible that the CCI surgery could lead to changes in the subjective 
responding of mice to CP55,940 which could produce different results for ZCZ011 analogs in 
drug discrimination.  
At the receptor level, there may be pharmacodynamic differences between ZCZ011 
analogs. The activity of ZCZ011 analogs in vivo may differ depending on the orthosteric probe 
being coadministered. The analogs examined in this study were tested using CP55,940 whereas 
ZCZ011 has previously been tested in combination with AEA in FAAH (-/-) mice as well as in 
combination with CP55,940 in C57BL6/J mice (Ignatowska-Jankwoska et al. 2015). Every 
compound was shown to have some effect in combination with CP55,940 in the triad assay 
suggesting that each compound reaches the CNS within the time points tested to produce a 
measurable interaction with CP55,940. No conclusion can be made however without quantifying 
drug levels in CNS as there remains the possibility of peripheral mechanisms of action.    
In the CCI model, the effects of ZCZ011 are presumed to be mediated through 
enhancement of endocannabinoid signaling at CB1 receptors (Ignatowska-Jankowska et al. 
2015). Upregulation of the endocannabinoid system with respect to AEA or 2-AG levels as well 
as CB1 receptor expression is known to occur in response to neuropathic pain (Petrosino et al. 
2007; Siegling et al. 2001). Thus, for ZCZ011, ABD1236, and GAT211, their antiallodynic 
effects may depend on increased endocannabinoid tone that results from the neuropathic pain 
state induced in the CCI model. Accordingly, the CB1 PAM may enhance the signaling of AEA 
and/or 2-AG at CB1 receptors. Alternatively, these modulators may act as allosteric agonists. 
Based on in vitro data, analogs of ZCZ011 possess some intrinsic agonist activity at CB1 
receptors. Studies on GAT211 have shown that its (R)- and (S)-isomers GAT228 and GAT229, 
respectively, bind to distinct allosteric sites on CB1 receptors where GAT228 behaves as an 
allosteric agonist and GAT229 is a PAM (Hurst et al. 2019; Laprairie et al. 2017). ZCZ011 and 
ABD1236 also feature a chiral center, which is lacking in the LDK series of compounds. Most 
LDK compounds are comparable to ZCZ011 in inhibition of cAMP accumulation and so the 
structural differences do not significantly affect this activity. None of the compounds tested 
behaved in a similar fashion as CB1 orthosteric agonist in the tetrad assay or drug discrimination 
paradigm. This result could be a function of dose in that some compounds may have CB1 agonist 
activity, but not at the doses tested. The potency of ZCZ011 analogs in vitro were significantly 
lower in comparison to CP55,940 so it is likely that a dose of 40 mg/kg did not result in drug 
concentration sufficient for agonist effects in vivo. LDK1729 produced small but significant 
effects on locomotor activity and body temperature; however, it did not produce significant 
effects in all four tetrad measures. A compound would need to induce all four tetrad effects to be 
considered a cannabinoid agonist. None of the compounds tested in this study substituted for the 
discriminative stimulus effects of CP55,940 in the drug discrimination paradigm. The allosteric 
agonist activity of ZCZ011 analogs does not predict agonist activity in vivo. The extent however 
to which ZCZ011 analogs function as PAMs or allosteric agonists may result in differences in 
PAM activity in vivo. Differential activity at CB1 receptor sites which mediate PAM or allosteric 
agonist effects may contribute to differences between ZCZ011 analogs in the triad and drug 
discrimination assay. For example, only ZCZ011 potentiated the effects of CP55,940 in all three 
measures of the triad assay whereas the other analogs only potentiated a subset of those effects. 
To attribute differences in activity in vivo to activity at specific binding sites however would 
require site-directed mutagenesis and transgenic expression of CB1 receptors.  
In the triad and drug discrimination paradigms, only CP55,940 was used as an exogenous 
CB1 orthosteric agonist. It is difficult to draw comparisons among these two assays and the CCI 
model for several reasons. First, in the CCI model, although ZCZ011 may augment 
endocannabinoid signaling through its actions as a CB1 PAM, the concentration of 
endocannabinoids at CB1 receptors is unknown. AEA or 2-AG could have been used in the tetrad 
and drug discrimination studies however it would be draw comparisons between assays in which 
the orthosteric agonists at work are administered exogenously or produced endogenously. The 
second reason is that neuropathic pain and antiallodynic effects in CCI are dependent on specific 
pathways which modulate pain. Drug discrimination is a measure of subjective drug effects and 
so has more to do with the affective component of cannabinoid-related behaviors. With respect 
to pain however, there is a sensory component in addition to the affective component. Therefore, 
CB1 PAMs may have a differential effect on the overt and subjective effects of cannabinoids. 
That is to say CB1 PAMs may affect only a subset of cannabinoid-related behaviors. GAT211 
potentiates the effects of CP55,940 in the triad assay but does not alter the potency of its 
discriminative stimulus. LDK1752 potentiated the discriminative stimulus of CP55,940 but had 
very little effect on its potency in the triad assay. Overall, the 2-phenyl indole class of CB1 
PAMs show differential modulation of the antiallodynic, overt-behavioral, and subjective drug 
effects of cannabinoids as measured in the CCI model of neuropathic pain, tetrad assay, and drug 
discrimination paradigm, respectively.  
 
Limitations  
 The first limitation of this study is that only CP55,940 was used as the orthosteric probe 
to study the effects of CB1 PAMs. ZCZ011 has been characterized in the triad assay and drug 
discrimination paradigm with both AEA and CP55,940 and there are ligand specific effects. In 
the triad assay, ZCZ011 potentiates the effect of CP55,940 in all three measures whereas it only 
potentiates the hypothermic effects of AEA (Ignatowska-Jankowska et al. 2015). Therefore, 
differences in activity compared to ZCZ011 or a total lack of activity for the other analogs may 
be attributed to ligand-dependent effects. Using either endocannabinoid AEA or 2-AG would 
have better allowed for comparison to CCI results wherein the mechanism of action of CB1 
PAMs are endocannabinoid-dependent. If ZCZ011 reduces CCI-induced mechanical allodynia 
by potentiating endocannabinoid signaling at CB1 receptors, then an endocannabinoid ligand 
should have been used in the triad assay and drug discrimination paradigm. The same applies for 
the in vitro characterization as it would be beneficial to know whether any ZCZ011 analogs 
exhibit ligand bias towards endogenous or exogenous cannabinoids. Doing so could help control 
for ligand-dependent effects however the difference still remains that in CCI the 
endocannabinoids would be produced endogenously rather than administered exogenously. The 
challenge however with studying the endocannabinoids is that AEA and 2-AG are rapidly 
hydrolyzed in vivo. AEA has been studied successfully with the use of FAAH (-/-) mice. 
Although MAGL (-/-) mice can be generated for study, they present some confounds in that they 
exhibit reduced CB1 receptor expression and function as well as anxiety-like behaviors (Deng et 
al. 2020; Imperatore et al. 2015; Schlosburg et al. 2010).   
In relation to the allosteric ligands, it is not known precisely how each interacts with CB1 
receptors. Structural and in vitro data suggest the isomers of GAT211 bind at distinct sites to 
mediate either PAM or allosteric agonist effects. Applying site-directed mutagenesis to CB1 
receptors and expressing those receptors in transgenic mice could offer a model to compare 
ZCZ011 analogs in terms of their CB1 binding interactions. The differences seen in vivo between 
the ZCZ011 analogs may depend on which binding sites are occupied and which residues are 
involved in binding.  
Another limitation in this study was in relation to dose selection. No effect was seen for 
GAT211 or LDK1747 at 40 mg/kg in drug discrimination and so it’s possible a higher dose 
could have had an effect however solubility then becomes an issue. A dose of 40 mg/kg for a 
ZCZ011 analog is approximately 10mM in terms of concentration. Studies on ZCZ011 in vitro 
used concentrations no higher than 1𝝁M which potentiated the pharmacological effects of AEA 
and CP55,940 (Ignatowska-Janowksa et al. 2015). Thus, it seems 40 mg/kg of a ZCZ011 analog 
should be sufficient to produce PAM effects however the exact concentration achieved at CB1 
receptors in vivo is unknown. Regardless, using another analog and having to exceed the dose of 
ZCZ011 which reverses allodynia would make that compound less relevant from a therapeutic 
standpoint and so it is perhaps unnecessary to test doses higher than 40 mg/kg. 
 Lastly this study was limited in the compounds available for study such as ABD1236 
which could not be obtained. ABD1236 was among the three compounds which exhibited 
antiallodynic activity in CCI and PAM activity in the triad assay (along with ZCZ011 and 
GAT211). Therefore, it would have been beneficial in testing the hypothesis to evaluate 
ABD1236 in the drug discrimination paradigm. LDK1729 and LDK1730 similarly remain to be 
evaluated in drug discrimination with CP55,940. Despite this limitation there appears to be 
sufficient evidence that the pharmacological effects of ZCZ011 analogs in vitro and in vivo do 
not predict their antinociceptive effects in the CCI model of neuropathic pain.  
 
Future Directions  
 Future directions for this study involve characterization of the remaining ZCZ011 
analogs (ABD1236, LDK1729, LDK1730) in the drug discrimination paradigm. It would be of 
interest to test whether ABD1236 potentiates CP55,940 dose-response generalization curve in 
drug discrimination. Further experimentation in drug discrimination could be done using either 
AEA in FAAH (-/-) mice or MAGL inhibitors in C57BL6/J mice to examine whether ZCZ011 
analogs differentially potentiate the subjective effects of either endocannabinoid. This 
experiment could help evaluate probe dependence for ZCZ011 analogs in drug discrimination. 
For the compounds evaluated in this study (GAT211, LDK1747, LDK1752), 40 mg/kg was the 
highest dose used and so future studies should examine whether these compounds alter the 
discriminative stimulus properties of CP55,940 at higher doses. An interesting question which 
arises from this study is whether any changes in the endocannabinoid system induced by CCI 
surgery alter the overt or subjective effects of cannabinoids as measured in the tetrad assay and 
drug discrimination paradigm. In other words, it is not known whether the CCI model produces 
any changes in the endocannabinoid system which modulate non-pain-related behaviors. If 
sciatic nerve injury in the CCI model results in an upregulation of the endocannabinoid system 
that enhances the sensory component of pain modulation, it may also produce changes in the 
affective component of cannabinoid-related behaviors. To test this hypothesis, it would require 
combining the CCI model with the drug discrimination paradigm in such a way that one can 
assess whether the CCI surgery alters the discriminative stimulus properties of a CB1 orthosteric 
agonist. To do this would require obtaining a dose-response for a CB1 agonist in drug-like 
responding and response rates then subjecting that cohort of animals to the CCI surgery or a 
sham surgery and see whether the dose-response relationships are altered. Subsequent to the 
surgery would be re-constructing the same dose-response curves to see if the CCI surgery 
produced any leftward or rightward shifts in CB1 agonist potency and whether that effect was any 
different from the sham surgery group. A challenge to this model would be that in the weeks it 
takes to build a dose-response curve in drug discrimination, the pain response thresholds of the 
mice would increase over time as they healed, making the model inconsistent. This problem 
could be overcome by using a between-subjects design, however that would require more 
subjects. Another question to examine in the future is whether the hypothesis holds true for a 
separate class of CB1 PAMs that are structurally distinct from the 2-phenyl indoles represented 
by ZCZ011.  
 
Conclusion  
 The purpose of this study was to examine the relationship between CB1 PAMs in the CCI 
model of neuropathic pain, tetrad assay, and drug discrimination paradigm. The results of this 
study indicate that there is no correlation for CB1 PAM activity between the three behavioral 
paradigms. The pathways which mediate the overt and subjective effects of cannabinoids are 
separate and distinct to the extent that compounds in the same class of CB1 PAMs exhibit 
activity which does not always translate between behavioral measures in vivo. The tetrad and 
drug discrimination paradigms are useful for inferring cannabimimetic effects and have been 
used to infer potential abuse liability of CB1 receptor ligands administered alone. However, the 
results from studies investigating CB1 PAMs in combination with CP55,940 in these assays did 
not predict efficacy in predicting antiallodynic effects in the CCI model. Similarly, a CB1 PAM 
which is effective in the CCI model may exhibit no PAM activity in the tetrad or drug 
discrimination assays in that they do not potentiate the dose-response relationships of orthosteric 
agonists; GAT211 is one such example. For CB1 receptor ligands tested in the CCI model of 
neuropathic pain, it remains important to assess those compounds in tetrad and drug 
discrimination to rule out any possible psychoactive effects. Thus, all three measures should be 
employed when studying the in vivo pharmacological effects of CB1 receptor ligands. Although 
the triad and drug discrimination assays do not appear to not offer a means to predict 
antinociceptive effects in the CCI neuropathic pain model, these assays possess utility to 
investigate the efficacy of CB1 ago-PAMs in neuropathic pain models, which lack 
cannabimimetic side effects associated with CB1 orthosteric agonists. Nevertheless, for ligands 
acting at CB1 receptors, the tetrad assay and drug discrimination paradigm should still be 
employed to screen for abuse liability. These assays are also required from a mechanistic 
standpoint. The CCI model does not yield any information about the mechanism of action of 
ZCZ011 analogs and whether they are acting as an agonist or PAM at CB1 receptors. The tetrad 
and drug discrimination paradigms therefore represent an indispensable tool to pharmacologists 
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